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ABSTRACT
Biological sample clean-up procedures were evaluated for the extraction 
of a range of /3-agonists. Once extracted the compounds were determined by 
immunoassay, electrochemical techniques and supercritical fluid 
chromatography (SFC).
Clenbuterol was isolated from liver tissue using matrix solid phase 
dispersion (MSPD). The technique was optimised for extract clean-up and 
recovery by evaluation of various wash and elution solvents using 
radiolabelled clenbuterol. Recovery of clenbuterol was >  90 % at three 
levels tested (1, 2 and 5 ng/g). MSPD was then applied to the extraction of 
other compounds in this class like salbutamol, mabuterol, cimaterol and 
terbutaline in the low ng/g range. For residues which occur as conjugates, an 
enzyme hydrolysis procedure was used. Sample extracts were assayed by 
radioimmunoassay (RIA) and enzyme immunoassay (EIA).
Cyclic voltammetry (CV) was used to study the electrooxidation of 
salbutamol, fenoterol and metaproterenol at unmodified and Nafion-modified 
carbon paste electrodes (CPE’s). All compounds were oxidised irreversibly 
at high positive potentials at the CPE. The Nafion-modified electrode allowed 
the accumulation of all compounds with time, resulting in an enhanced 
sensitivity. The application of the Nafion-modified electrode to the analysis 
of fenoterol in human urine and serum extracts was demonstrated at the 10'7 
and 10'6 M level, respectively. In this case the more sensitive differential 
pulse voltammetric (DPV) mode of detection was chosen.
Finally, the application of supercritical fluid extraction (SFE) for the 
isolation of /3-agonists was investigated. Extracts of pure standards and liver 
samples, dispersed on support media (Celite and C18 material), were assayed 
by supercritical fluid chromatography (SFC) with UV detection.
CHAPTER 1
A REVIEW OF METHODS FOR THE ANALYSIS OF 0-AGONISTS IN
BIOLOGICAL MATRICES
1.1 INTRODUCTION
This chapter focusses on analytical procedures which are used for the 
determination of the class of compounds known as /32-agonists. /?2-agonists are 
synthetic derivatives of naturally occurring molecules (catecholamines) and, 
as the name suggests, they bind to /32-receptors on nerve cells to produce 
directly observable physiological effects (e.g. increase in heart rate). Their 
mechanism of action follows that of norepinephrine and epinephrine which, 
when released at nerve endings into the bloodstream, represent an important 
aspect of the functions of the autonomic (or involuntary) nervous system. This 
system controls many organs (cardiovascular, gastrointestinal etc) and 
metabolic processes. The autonomic functions are divided into two main 
components; the parasympathetic and sympathetic systems. The latter system 
is responsible for the "fight or flight" reaction. In such situations, energy is 
required immediately, and heart rate and blood flow through coronary vessels 
and skeletal muscles increase. These reactions are mediated by the 
catecholamines, epinephrine and norepinephrine. The structures of these two 
physiologically important compounds are shown in Figure 1.1
How a /32-agonist, whether synthetic (e.g. clenbuterol) or natural (e.g. 
epinephrine), actually brings about a response is dependent on a series of 
biochemical reactions at the /32-receptor in the cell membrane. The /?2- 
adrenergic receptor model, shown in Figure 1.2, shows how the response is
Figure 1.1
(a)
(b)
Chemical structures o f (a) epinephrine and (b) norepinephrine
-3-
Plasma
membrana
Response <----------- E*p R protein
S'AMP
(inactive)
Figure 1.2 (3-adrenergic receptor model
achieved. The j82-receptor (R) is coupled via a protein (guanine-Gs) to the 
enzyme, adenyl cyclase (AC). Upon /3-agonist-receptor binding, the G protein 
stimulates AC, which in turn stimulates the formation of a growth factor, 
cyclic adenosine 3, 5-monophosphate (cAMP). cAMP stimulates protein 
kinase (PK) activity, or it can itself be inactivated by phosphodiesterase 
(PDE). A regulatory protein (R protein) is split off and active PK stimulates 
phosphorylation of enzymes which can trigger the response. /3-receptor 
activity results in the following effects; heart-rate increase, relaxation of 
muscle tissues in bronchi, uterus and intestinal wall, and the stimulation of 
insulin release and glycogen breakdown. The major clinical indications for 
use of /32-agonists are respiratory diseases and tocolysis. In recent years it has 
been established that certain synthetic /32-agonists, when administered to farm 
animals at multiples of the therapeutic dose, cause a shift in the flow of 
nutrients away from adipose tissue towards muscle tissue (commonly called a 
repartitioning effect) [1]. The net result of such practices is the production of 
a leaner carcass. The toxicological and pharmacological implications of 
residues present in edible tissues has led to the banning of these compounds 
as growth enhancing agents within the EU.
j32-agonists are generally divided into two main groups, the substituted 
anilines which include clenbuterol and cimaterol, and the substituted phenols 
which include salbutamol and terbutaline. Figure 1.3 gives the chemical 
structure of the /32-agonists studied, representing compounds from both groups.
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Figure 1.3 Chemical structures o f the ß-agonists studied
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The compounds possess a common /3-hydroxyamino group on the side chain, 
but are differentiated from each other by varied substituents on the aryl moiety 
and the terminal amino group. The hydroxyl group(s) on the aromatic ring 
of the substituted phenols is a target for glucuronide or sulphate conjugate 
formation [2]. Hence for determination of total residue concentration, a 
deconjugation stage must be incorporated into any assay procedure.
Selection of the appropriate biological sample for analysis is an 
important criterion for this type of compound. Plasma and urine may be 
monitored, but the levels are usually low (ppt to low ppb) as the compounds 
have short half-lives and are cleared rapidly from the body. Organs which 
accumulate /32-agonists are more suitable for monitoring usage. Work by 
Meyer and Rinke has shown that the liver contains detectable clenbuterol 
residues for up to two weeks after withdrawal of the drug from the animals 
diet [3]. More recently, several authors have reported that eye fluids and 
tissue fractions may attain concentrations an order of magnitude higher than 
in liver [4, 5].
The ideal determination procedure for /5-agonists would combine 
efficient clean-up of sample matrix with sensitive measurement of analyte(s). 
For sample clean-up, a wide range of approaches have been adopted. 
Classical solvent extraction procedures have resulted in good recoveries of the 
substituted anilines such as clenbuterol and mabuterol [6], but are less 
effective for the more polar compounds, such as salbutamol [7]. Emphasis
has now been placed on safer and more rapid alternatives like solid phase 
extraction (SPE), matrix solid phase dispersion (MSPD) and immunoaffinity 
chromatography (IAC). Such techniques may be more suited, also, for a 
multiresidue approach to analysis. After sample clean-up has been achieved, 
the compound(s) may be detected by any one of a number of sensitive 
techniques. High performance liquid chromatography (HPLC) with 
fluoresence or electrochemical detection has proved sensitive for one or a 
combination of /3-agonists [7-9]. Ultraviolet (UV) detection only gives 
optimum sensitivity after a post-column derivatisation procedure [10]. 
Immunoassay techniques, such as radioimmunoassay (RIA) and enzyme 
immunoassay (EIA) or radioreceptor assays are most sensitive detection 
systems for 0-agonists. Procedures have been reported, for the analysis of a 
/3-agonist of choice (i.e RIA) [11] or a number of /3-agonist compounds (i.e. 
radioreceptor assay) [12] in this class. Mass spectrometry is the most popular 
confirmation technique used in this field. Methods based on gas 
chromatography-mass spectrometry (GC-MS) have been developed for many 
0-agonists [13, 14] and, more recently, clenbuterol has been determined using 
methods based on liquid chromatography-mass spectrometry (LC-MS) [15].
This review provides an up-to-date evaluation of the methodologies 
developed to determine /3-agonists in complex biological samples. Emphasis 
has been placed on sample purification procedures leading to extracts
containing one or a combination of jS-agonists which can be identified and 
quantified by an appropriate detection system.
1.2 SAMPLE PREPARATION PROCEDURES
Before a clean-up procedure may be carried out the sample must be 
prepared in such a way that optimised conditions for the extraction of the 
analyte(s) may be used. This is particularly relevant for complex matrices like 
biological samples, the nature of which determines the kind of pretreatment 
step required. For liquid samples, which include urine and plasma, suspended 
matter may be removed by centrifugation [13] or filtration [16]. For residues 
which occur as conjugates, enzyme and acid hydrolysis procedures have been 
used, prior to sample clean-up. An enzyme hydrolysis procedure on 
clenbuterol-incurred urine was carried out by Hooijerink et al. but their results 
showed that this compound forms relatively low levels of glucuronide (5%) 
conjugates (sulphate conjugates not found) [17]. For the phenolic-type (3- 
agonists conjugate formation has been reported [2, 18]. Enzyme hydrolysis 
of salbutamol was carried out in urine, after the sample was adjusted to pH 
5.0, by incubation with a dilute solution of enzyme (glucuronidase/sulphatase) 
at 37°C for between 16-18 h [13, 19]. Acid hydrolysis has been reported for 
the deconjugation of O-sulphate esters of metaproterenol in plasma samples 
[20]. After protein precipitation using trichloroacetic acid, the plasma
supernatant was incubated with 0.2 ml 0.2 M hydrochloric acid at 65 °C for 
90 min and free metaproterenol was extracted using C18 SPE after pH 
adjustment to 10.0. Alternatively, the hydrolysis step can be omitted 
altogether; incurred residues of salbutamol may be extracted from urine by 
cation-exchange SPE and analysed as the conjugate by MS [21].
Solid samples, which include liver and muscle, require a more intensive 
sample pretreatment stage. The analyte(s) must be exposed to extracting 
solvents to optimise the conditions for extraction. This is accomplished, in 
part, by mechanical dispersion using a mincer and/or a homogeniser. The 
most popular approach for tissue break-up is the homogenisation of samples 
in water, acid or an aqueous buffer. Following centrifugation, the supernatant 
may be treated in various ways, made acidic or alkaline and extracted directly 
[14, 22] or pretreated further e.g. removal of fats using solvent extraction [4]. 
For the phenol-type /3-agonists, a deconjugation step is required; useful 
studies have been carried out which show that the main salbutamol metabolite 
in calf tissue samples, including liver, is the sulphate conjugate [23].
The use of ultrasonication to extract /3-agonists from a tissue/aqueous 
acid medium has also been reported [24, 25]. An extraction time of 15 min 
was sufficient and the pH of the supernatant was adjusted to optimise further 
clean-up steps. In order to digest proteins, enzymatic digestion at 55°C has 
been described [26, 27]. Lyophilization (freeze drying) of rat tissue samples
has been carried out prior to extraction [28]. For eye tissues sample 
pretreatment is analogous to that of liver and muscle samples [4].
1.3 SAMPLE CLEAN-UP/EXTRACTION OF /3-AGONISTS
The main goal of the sample pretreatment step(s) is to produce a 
primary extract which can be easily cleaned-up using an appropriate extraction 
procedure. Various types of sample clean-up procedures are available: 
conventional liquid-liquid partitioning, solid phase extraction methodology, 
matrix solid phase dispersion and immunoaffinity chromatography. In some 
cases these procedures may be used in combination to obtain highly purified 
extracts.
1.3.1 Liquid-liquid extraction
Originally, liquid-liquid extraction was the standard method for isolating 
drug compounds from biological samples. Unfortunately, this technique is 
relatively time-consuming especially for the extraction of polar compounds or 
a combination of compounds with various chemical properties. The main 
approach to /3-agonist extraction has been to adjust the pH of the sample above 
the pKa of the compound (usually >  9.0) to achieve deprotonation, followed
by partitioning with an organic solvent. Most of the earlier methods for 
clenbuterol analysis adopt this type of clean-up strategy. Diquet et al. devised 
an extraction method for clenbuterol from mouse plasma, the compound being 
extracted at high pH into chloroform [29]. Although the recovery of drug was 
low (45%), the use of an internal standard, yohimbine, allowed reproducible 
measurement of the levels present. Higher recovery, from urine, of 80% was 
reported by Brunn, using dichloromethane as the extraction solvent [30]. 
Diethyl ether was the chosen solvent for the extraction of clenbuterol from 
bovine urine [12] and rat brain tissue [8]. The latter publication focusses on 
the lipophilic characteristics of clenbuterol; the drug penetrates through the 
blood-brain barrier in rats at pre- or post-natal development. For the more 
hydrophilic compound, salbutamol, ethyl ether was the extraction medium 
chosen [31]. In our laboratory, extraction of salbutamol with diethyl ether 
was found not to be possible, due presumably, to its hydrophilic character.
For sample extracts which are determined by mass spectrometry, the 
clean-up step must be particularly intensive. Blanchflower and co-workers 
performed multiple diethyl ether extractions in combination with acid back 
extractions to achieve a purified extract suitable for GC-MS analysis of 
clenbuterol [32]. Girault et al. measured clenbuterol in a wide range of 
bovine biological samples; pretreated samples were extracted at high pH using 
ethyl acetate, back extracted into dilute acid, before washing (ethyl acetate: 
hexane, 2:1) and final re-extraction into ethyl acetate [14, 33]. Forster et al.
used a similar procedure but with tertiary butyl methyl ether (TBME) as the 
main extraction solvent [34]. Fuerst et al. improved sample clean-up by 
washing plasma samples with dichloromethane prior to extraction of 
clenbuterol with TBME [35]. Other authors have reported extraction 
procedures for clenbuterol [4, 11] and the more hydrophilic compound, 
fenoterol [18], based on the use of this solvent. For the latter extraction, 
adjustment of pH to exactly 9.5 allowed for the isolation of fenoterol from its 
conjugates.
In some cases, more than one organic solvent is required to extract the 
compound effectively. Horiba et al. studied the occurrence of mabuterol and 
its metabolites in urine samples [36]. Extraction, after sample evaporation and 
salting out steps, was carried out at pH 10 using ethyl acetate: acetone (3:1). 
Acidic and neutral metabolites were selectively removed after pH manipulation 
and further solvent extraction. A specific double extraction procedure for 
salbutamol in plasma samples was reported by Loo et al. [37]. Selective 
extraction of salbutamol from its main sulphate metabolite was achieved using 
methyl acetate. The solvent was evaporated, washed with a 
tetrahydrofuran/TBME mixture and extracted into a basic solution for analysis. 
Increased recoveries have been obtained by using a more polar extraction 
solvent mixture. This is achieved by the addition of a small proportion (10- 
30%) of a more polar solvent such as butanol. Recoveries of >  90% were 
obtained for aniline-type /3-agonists using a 9:1 mixture of diethyl ether: 2-
butanol [6] or TBME: n-butanol [38]. For the extraction of a wider range of 
/3-agonists, representing compounds from both groups, t-butanol: ethyl acetate 
(3:7) was the chosen medium [27]. An alternative approach is the 
combination of ion pair/liquid-liquid extraction methodology for compounds 
which are charged in biological matrices. Di(2-ethylhexyl)phosphate (DEHP) 
has been used as an ion-pair reagent for salbutamol extraction into chloroform 
from plasma samples [39]. The compound was then back extracted into dilute 
acid prior to HPLC analysis. This procedure was also adopted by Wu et al., 
but with the inclusion of an internal standard, metaproterenol [40]. Tan and 
Soldin carried out preliminary C,g SPE clean-up prior to ion pair extraction 
using both DEHP and 1-heptane sulphonic acid for salbutamol and an internal 
standard, fenoterol [41]. The extraction solvent was ethyl acetate and a 
salbutamol recovery of 80% was achieved. A more rapid alternative, also 
based on DEHP/ ethyl acetate extraction was described by Miller and 
Greenblatt [42]. The most recently-reported work in this area, by Sagar et al., 
described the use of the ion pair reagent, sodium dodecyl sulphate, in 
combination with ethyl acetate for the extraction of salbutamol from human 
plasma (recovery 90%) [43].
1.3.2 Solid phase extraction methodology
In recent years, solid phase extraction (SPE) and immunoaffinity 
chromatography (IAC) have superceded traditional solvent extraction 
procedures for the isolation of drugs from biological matrices. These types 
of techniques, which perform sample clean-up and in some cases, analyte 
preconcentration, are particularly advantageous as they can be easily 
automated, require low solvent usage, and are generally less time consuming 
and less labour intensive. From the point of view of /3-agonists, solid phase 
extraction cartridges have a variety of special properties which allow better 
extraction of the more hydrophilic compounds, such as salbutamol and 
terbutaline. The two main SPE approaches reported for /3-agonists have been 
either off-line extraction (adsorption, reversed phase, ion-exchange and mixed 
phase) or on-line extraction (reversed phase and ion exchange).
1.3.2.1 Off-line extraction
1.3.2.1.1 On-column liquid-liquid partitioning
Adsorption columns, containing hydrophilic packing material 
(diatomaceous earth) have been used to adsorb and distribute urine and tissue 
supernatants over a large surface area, after which the /3-agonists of interest
may be eluted from the column with a water-immiscible solvent. The columns 
have a large capacity and hence are suitable for large sample volumes (up to 
20 ml). Before application, the samples are pH-adjusted to 10 or greater to 
render the compound uncharged and allow ease of extraction into the organic 
phase. An early use of this type of column was described by Eddins et al. for 
application to clenbuterol in urine samples [44]. Alkalinised urine was applied 
to a "Clinelut" column and allowed to equilibrate for 10 min before elution of 
clenbuterol with three column volumes of hexane. This method was modified 
slightly by Degroodt et al. to include animal tissues extracts [45]. Brambilla 
et al. also adopted this approach for application to the aniline-type compounds 
in urine [46] and vitreous humour [47]. In this case the extraction solvent was 
dichloromethane. Other elution solvents used were t-butyl methyl ether for 
clenbuterol [17] and a mixture of toluene: dichloromethane (3:1) for 
clenbuterol and cimaterol [10]. This adsorption mechanism has not been 
extended to include the phenolic 0-agonists as they are not eluted from the 
column using non-polar or semi-polar solvents. Leyssens et al. used an 
alumina neutral SPE column for improved clean-up of liver homogenates: the 
aniline 0-agonists were easily extracted (e.g. mabuterol recovery 85%) but for 
the phenolic compounds (e.g. salbutamol and terbutaline) the recovery was 
poor (<  40%) [27].
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1.3.2.1.2 Reversed-Phase SPE
0-agonists are particularly suited to reversed-phase SPE due, in part, 
to their relatively non-polar aliphatic moiety which can interact on 
hydrophobic (octadecyl (C18) and decyl (C8)) stationary phases. Optimum 
retention is achieved by adjusting the sample pH to >  10, as for liquid 
extraction. Much of the scientific literature deals specifically with C18 SPE, 
with authors adopting very similar approaches for sample application, washing 
and elution procedures. In most cases methanol or a solvent of similar 
polarity was used to activate the column packing material prior to equilibrating 
with water or an alkaline buffer. After sample application, water or 
water/methanol (usually with a high water content) washed off matrix 
interferences before elution of the 0-agonist(s) with methanol. The literature 
is replete with examples of Clg SPE used in this way to extract clenbuterol 
[48, 49], salbutamol [24, 50], terbutaline [51], fenoterol [52], cimaterol [9] 
and bambuterol [53].
1.3.2.1.3 Ion-exchange SPE
Drug retention through ion-exchange mechanisms has been reported for 
the more polar, ionisable 0-agonists like salbutamol and terbutaline. These 
compounds have been retained on either XAD-2 cation exchange columns or
unmodified silica columns. For the former type of column, procedures for the 
extraction of salbutamol [54] or salbutamol conjugates [21] have been 
described. Salbutamol is charged over the entire pH range allowing a 
retention mechanism with the negatively-charged resin. The drug was 
removed from the column with methanol. Terbutaline was separated from 
plasma on a AGX-2 resin, eluted in alkaline buffer and re-extracted into 
butanol [55]. Unmodified silica, also acts as an ion-exchanger with basic 
analytes. Retention occurs at pH values between 5.5 and 8.0, where the 
surface hydroxyl groups on the silica become increasingly ionised and attract 
the positively-charged amine on the 0-agonist molecule. SPE procedures, 
based on silica retention, have been decribed for application to salbutamol [56] 
and salbutamol and terbutaline [57] in plasma samples.
1.3.2.1.4 Mixed phase interactions
The SPE columns already described are suitable for individual 0- 
agonists or groups of 0-agonists possessing similar chemical properties. 
However, difficulties can arise when a multicomponent extraction procedure 
is required. Optimisation of the residue extraction procedure for clenbuterol- 
like compounds can result in a reduced recovery for salbutamol-like substances 
[13]. To improve retention of the more polar compounds, some authors have 
tried "mixed phase" columns which have both lipophilic and ion-exchange 
properties, depending on the pH and the elution solvent. In practice, the
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sample is added to the column at a neutral pH and the drug is retained by 
hydrophobic interaction. Then the column is acidified to protonate the drug 
and promote its ion-exchange retention on the S 0 3" group on the resin. 
Methanol serves as a broad spectrum wash solvent and the compounds of 
interest are eluted in methanol containing a small percentage of concentrated 
ammonia.
Dumasia et al. developed a mixed phase SPE procedure for selected /3- 
agonists from horse urine [19]. In this case 1.0 M acetic acid was used to 
promote ion-exchange conditions, and ethyl acetate containing 2% ammonium 
hydroxide was the elution solvent. Gabiola adopted a similar procedure to 
extract salbutamol, terbutaline and clenbuterol, including conjugates, from 
bovine urine [58]. Leyssens et al. extended the procedure to cover seven /3- 
agonists, containing compounds from both major classes [27]. The only 
difference was the elution solvent, i.e. dichloromethane: isopropanol (8: 2) 
containing 2% ammonia. Recoveries from urine were adequate (e.g. 
clenbuterol 51%, mabuterol 82%) but liver samples required two additional 
clean-up steps (liquid extraction and alumina SPE), resulting in a procedure 
only suitable for the clenbuterol-type compounds. Montrade et al. improved 
the recovery of the salbutamol-like compounds after optimisation of the 
percentage ammonia in the elution solvent. A 3  % (v/v) concentration in ethyl 
acetate resulted in good recovery of thirteen /3-agonists in urine samples [13].
1.3.2.2 On-line solid phase extraction
On-line SPE is a clean-up technique which is used in conjunction with 
chromatographic procedures, principally HPLC. The analyte is retained on 
a preconcentration column positioned between the injector and the analytical 
column and, after a washing step, desorbed and re-routed to the analytical 
column for separation and detection.
On-line methods have been reported for /3-agonist extraction based on 
either reversed-phase or ion-exchange principles. With respect to the former 
category, Sagar et al. described an on-line reversed-phase preconcentration 
procedure for terbutaline [59] and terbutaline and salbutamol [60] from plasma 
samples. Plasma was injected directly onto a small Clg column (10 cm x 1.5 
mm) and, after washing with water, the /3-agonists were back-flushed with 
mobile phase to the analytical column. Similar procedures for terbutaline 
retention were described by Edholm et al. [61] and Berquist and Edholm [62]. 
Tamisier-Karolak et al. used a combination of off-line and on-line reversed- 
phase SPE to produce highly purified extracts, containing both salbutamol and 
fenoterol, for HPLC analysis [63]. On-line ion-exchange SPE was described 
by Oosterhuis and van Boxtel [64]; salbutamol and bemathan were retained 
on a cation exchange (Partisil SCX) column followed by desorption and 
subsequent separation on a reversed phase column.
1.3.3 Immunoaffinity chromatography (IAC)
I AC is a SPE-type technique which relies on antigen: antibody 
interactions to preconcentrate the analyte(s) of interest. The technique has only 
recently been applied to the extraction of 0-agonists, but already it has found 
widescale acceptance due to its high specificity and sample clean-up efficiency. 
A review by van Ginkel covers many of the characteristics of the IAC 
procedure [65]. To produce antibodies suitable for IAC columns, an animal 
(e.g. rabbit) is immunised with the test analyte conjugated to a protein (e.g. 
human serum albumin). Serum is harvested from the treated animals and 
immunoglobulins with specific cross-reactivity to the analyte (and similar 
compounds) is purified by ammonium sulphate precipitation. The purified 
immunoglobulin is bound to a sepharose gel and incorporated into a column. 
IAC may be applied either off-line as an extraction procedure or on-line as an 
extraction/preconcentration procedure.
The first selective on-line extraction/concentration procedure for a 0- 
agonist (clenbuterol) based on IAC was carried out by Haasnoot et al. [66, 
67]. Urine or tissue supernatants were applied to the column by valve 
switching and, after washing with water, clenbuterol was desorbed and flushed 
to a C18 analytical column with 0.01 M acetic acid. This system, could not 
be developed for multicomponent analysis because of the low cross-reactivity 
shown by the antibody to other 0-agonists. Schilt et al. overcame this
problem by off-line concentration of the eluate from the the IAC column and 
used GC-MS to detect the low cross-reacting compounds in the low ppb range 
[68]. Other IAC methods performing in a similar way have been described 
for salbutamol extraction from urine [69] and tissue [28].
van Ginkel et al. [25] explored the possibility of a less specific antibody 
which could be directed against a broader range of 0-agonists. A mixture of 
antibodies, cross-reacting with both the N-t-butyl and the N-iso-propyl groups 
of 0-agonists, was produced. This resulted in a more robust multi-0-agonist 
extraction/preconcentration procedure, and, coupled with GC-MS 
determination, gave good recovery of four compounds. With further advances 
in clean-up capability expected, it is likely that IAC procedures in conjunction 
with HPLC and MS, will soon become the standard analytical technique for 
0-agonist analysis.
1.4 SEPARATION OF 0-AGONISTS
After the extraction/clean-up step, chromatographic separation is usually 
required for selective detection of 0-agonist(s). Reversed-phase HPLC has 
been the most popular separation technique for 0-agonists, due to the 
hydrophobic interaction of the molecules with C18 or C8 stationary phases. 
Separation methods based on these principles has been reported for clenbuterol 
[8], salbutamol [42] and a mixture of 0-agonists [9]. For compounds which
are charged (salbutamol, terbutaline), ion-pair chromatography has been used. 
Typical ion-pair reagents are heptane sulphonic acid [41] and sodium dodecyl 
sulphate [10]. Alternatively, charged compounds can interact on a cation 
exchange column [57, 64]. Because the /3-agonist molecule contains a chiral 
centre, enantiomers have been separated by chiral HPLC [70, 71]. In this 
case the stationary phase is made up of /3-cyclodextrins or glycoproteins bound 
to silica. Normal phase HPLC has been less popular. One reported normal 
phase method for the separation of salbutamol involved a silica column and a 
mobile phase of 0.25% acetate buffer in methanol [56].
Separation of /3-agonists by gas chromatography (GC) is not ideal as 
these relatively polar compounds must first be derivatized. However, the 
main advantage of using GC for separation purposes is the choice of very 
sensitive detectors, including mass spectrometers. The separation may be 
carried out using the classical packed column [72] or, for improved efficiency 
and better applicability to multiresidue analysis, use of a capillary column is 
the preferred option [19, 27, 58].
High performance thin layer chromatography (HPTLC) may be used, 
but generally this technique has been applied only as a qualitative technique. 
Extracts are spotted onto silica plates and compounds of interest are separated 
as bands by the mobile phase. Henion et al. reported the separation of 
clenbuterol from its urine matrix on a HPTLC plate [73]. The compound was 
converted to an azo dye for visual confirmation prior to removal of the
developed spot for tandem mass spectrometric analysis. Similar procedures 
were carried out for other aniline-type /3-agonists in a variety of matrices [10, 
30, 46]. Methods have been reported for the separation of salbutamol 
followed by conversion to its indoaniline dye and detection by absorption 
microdensitometry [24, 54],
Capillary zone electrophoresis (CZE) and related methods have also 
appeared in the literature, but only for measurement of relatively high 
concentrations of /3-agonists [74-76], Whether or not they can be applied to 
biological sample extracts at the ppb level remains to be seen.
1.5 DETECTION OF /3-AGONISTS
After a suitable extraction/clean-up procedure has been carried out, the 
/3-agonists may be detected by spectrometric, electrochemical, immunological 
or mass spectrometric techniques, the choice of which depends on the required 
sensitivity. Published methods for /3-agonists in biological samples have 
focussed on either measurement of drug levels after therapeutic dosing or after 
illegal (growth enhancing) use. In general, the HPLC-based detector options 
have been suitable for measuring /3-agonists in the range 1 to 15 ng/ml, the 
plasma concentrations which occur following therapeutic doses [56]. Residue 
testing, however, requires detection systems which can detect /3-agonists at sub 
ng/g level (0.5 ng/g is the maximum residue limit (MRL) set in the UK for
clenbuterol in edible tissues) [77]. For this purpose the more sensitive 
immunoassay or mass spectrometric methods are used and, in the case of the 
latter technique, additional information concerning the structure of the /13- 
agonist molecule(s) may be obtained which allows for confirmation of the 
presence of specific residues.
1.5.1 Spectrometric Detection
Measurement of /3-agonists by HPLC with UV spectrometric detection 
has resulted in low detection limits due to the presence of strong 
chromophores. Methods have been reported for clenbuterol at wavelengths 
between 222-245 nm [8, 44, 66], and a mixture of 0-agonists (clenbuterol, 
cimaterol, salbutamol) at a compromise wavelength of 260 nm [9]. In the 
case of the method reported by Botterblom et al. [8], the method was limited 
by the detector sensitivity (limit of detection 33 ng/ml), a problem which may 
be overcome by using a post-column derivatization procedure. In this 
procedure, reagents (consisting of sodium nitrite and nitric acid to cause 
diazotization, ammonium amidosulphonate to remove excess nitric acid and N- 
(l-naphtyl)ethylenediamine which binds to the diazonium salt to form a light- 
absorbing product) are introduced into the mobile phase, post-column, to 
derivatise the 0-agonists into diazo dyes. The absorbance for the products 
(derivatized clenbuterol; Xmax = 493 nm and derivatized cimaterol \ max =
537 nm) was higher and resulted in limits of detection for the compounds in 
liquid and solid samples of 0.1 ng/1 and 0.2 ng/g, respectively [10, 78]. A 
combination of UV and electrochemical detection has recently been shown to 
result in unequivocal confirmation of residue-positive samples [17].
An alternative detector option, fluoresence detection, confers the 
additional advantage of selectivity to the detection of /3-agonists. This type of 
detection is particularly suitable for the resorcinol and catechol /3-agonists due 
to the intrinsic fluoresence of the aromatic phenolic structure. Many methods 
have been reported for salbutamol detection, with typical excitation and 
emission wavelengths at 225 nm and 310 nm, respectively [7, 39, 42]. These 
wavelengths are suitable for the detection of other related compounds like 
metaproterenol [20, 40] and terbutaline [20]. The sensitivity of the detection 
may vary, but detection limits of 1 ppb and lower have been reported [39,
56].
Quantification of analyte bands for HPTLC-based methods is 
accomplished by visual observation or densitometric measurements. For the 
latter detection mode, light of suitable wavelength is directed onto the TLC 
plates and the amount of light transmitted or reflected by the band is 
measured. Clenbuterol may be detected as a coloured band after reaction with 
Ehrlichs reagent [45]. Salbutamol was converted to its indoaniline derivative 
and quantified by absorption microdensitometry at 650 nm [24, 54].
1.5.2 Electrochemical Detection
Electrochemical detection is suited to /3-agonists due to the presence of 
the oxidisable amino/hydroxyl groups on the aromatic part of the molecule and 
the amino group on the aliphatic moiety. Interesting and informative 
electrochemical studies have been carried out which demonstrate the behaviour 
of salbutamol [80] and clenbuterol and mabuterol [6] at a glassy carbon 
electrode (GCE). The studies show that 0-agonists, as a class, are oxidised 
irreversibly at carbon electrodes at high positive potentials.
The bulk of the literature reports HPLC linked with electrochemical 
detector methods for detection of therapeutic levels of 0-agonists in urine and 
plasma. Hauck and Brugger described the detection of clenbuterol (at + 1 .2  
V vs Ag/AgCl reference) above 10 ng/ml using a GCE [48], A more 
sensitive electrochemical detection method, also employing a GCE (set at 
+  1.15 V vs the reference electrode), reported clenbuterol determination as 
low as 1 ng/ml [29]. Qureshi and Eriksson developed a method based on 
either GCE or carbon paste electrode (CPE) detection of aniline type 
compounds at +0.75 V [6]. Limits of detection of 0.5 ng/ml (clenbuterol) 
and 2.0 ng/ml (mabuterol) were achieved and an electrode pretreatment step 
(oxidation of electrode at high positive potentials) was described. A GCE 
detector was used to measure salbutamol and fenoterol [41] and salbutamol 
enantiomers [70]. Other forms of the carbon electrode used in this field were
the carbon paste rotating electrode for salbutamol [64] and the vitreous carbon 
electrode for terbutaline [81]. Sagar et al. developed methods based on 
detection of the phenolic /3-agonists (salbutamol, terbutaline) using a micro 
carbon fibre electrode [43, 59-60]. Advantages of this type of approach 
include low charging current and increased mass transport. The electrode 
potential used was + 1.3  V and electrode pretreatment procedures were 
described. A novel two-GCE detector approach for salbutamol and fenoterol 
was reported by Tamisier-Karolak et al. [63]. The operating potentials of the 
two electrodes were set at +0 .5  V (the potential where no oxidation occurred) 
and + 0 .9  V (optimum oxidation) and the difference in signals was recorded. 
A limit of detection of 0.5 ng/ml was reported.
1.5.3 Immunoassay Procedures
Immunoassays, including radioimmunoassay (RIA) and enzyme 
immunoassay (EIA), are highly favoured procedures due to their low detection 
capability, allowing the measurement of residues at 0.5 ng/g and lower. The 
EIA option has proved more popular in recent years but both techniques can 
handle large sample numbers and may require less sample clean-up than for 
other techniques. The procedures leading to the production of antibodies 
(described in section 1.3.3), are relevant also for immunoassay techniques.
Commercial kits for both techniques are available for single or multianalyte 
determination.
1.5.3.1 Radioimmunoassay
The first RIA procedure for a /3-agonist compound was reported by 
Kopitar and Zimmer for the pharmacological studies on clenbuterol in animal 
tissue [82]. Delahaut et al. described the development of a more specific RIA 
method for the determination of clenbuterol after its administration to animals 
as a growth enhancing agent [11]. The antiserum had 100% cross-reactivity 
to clenbuterol and lower cross-reactivity to other /3-agonists (<  10%), and 
was applicable to extracts from plasma, urine and faeces containing less than
0.5 ng/g (ml) level. A kit has been produced for measurement of salbutamol 
using an anti-salbutamol antiserum [69]. A method by Loo et al. [37] 
described the use of a specific RIA for the detection of free forms of 
salbutamol after the conjugates were removed from plasma by liquid-liquid 
extraction. Adam et al. reported an interesting RIA procedure for the 
determination of salbutamol using a monoclonal antibody [83]. The antibody 
was synthesized in mice against the 0-(3-carboxypropionyl) derivative of 
salbutamol linked to bovine serum albumin. Moreover, the antibody showed 
a high cross-reactivity (75%) to clenbuterol. Rominger et al. developed a 
specific RIA procedure for fenoterol which consisted of an antibody cross­
reacting with the different sterioisomers of fenoterol and radiolabelled [125I]- 
fenoterol [18]. The procedure measured fenoterol at the low pg/ml level in 
biological fluid extracts.
Radioreceptor assays have been developed which are similar to RIA but 
which use the binding of /3-agonists by receptors, instead of antibodies, as the 
analytical principle [12]. The method was based on competition between a 
radioactive tracer (3H-dihydroalprenolol) and aniline-type /3-agonists for 
binding to receptors (plasma membranes). Although the limit of detection 
reported, 2.4 ppb, was relatively high, this approach merits further 
investigation.
1.5.3.2 Enzyme-immunoassay
EIA has progressed in the last decade as a sensitive and reliable 
determination procedure in residue analysis. The first EIA for clenbuterol was 
developed by Yamamoto and co-workers [84], a selective double antibody and 
heterogenous immunoassay based on competition for binding between 
clenbuterol and its /3-D-galactosidase-labelled analogue to a clenbuterol 
specific antibody, followed by selective binding of the antibody-bound enzyme 
hapten with a second, immobilised antibody. The activity of the enzyme was 
determined fluorometrically after addition of substrate. Many of the principles 
developed in this procedure have been incorporated into EIA procedures
presently being used. The EIA procedure developed by Degand et al. was 
based on the competition between clenbuterol and diazo-clenbuterol- 
horseradish peroxidase (HPO) for the antiserum [22]. The procedure had the 
capability of determining clenbuterol at levels below 0.5 ppb. An EIA 
procedure, containing an antiserum specific for clenbuterol and also utilising 
a HPO-based enzyme conjugate, was developed to monitor urine and tissues 
from clenbuterol-medicated farm animals [85]. The antiserum had cross­
reactivities to salbutamol and cimaterol of 26.3% and 1.3%, respectively. 
EIA kits containing a salbutamol-based enzyme conjugates, either salbutamol- 
4-carboxymethylether-HPO [4] or salbutamol hemisuccinate-HPO [86-88] were 
used to determine clenbuterol in urine and tissue extracts. Angeletti et al. [89] 
and Paleologo-Oriundi [90] reported EIA assays which could determine four 
/3-agonists (clenbuterol, mabuterol, salbutamol and terbutaline) in biological 
samples (urine, serum), using anti-0-agonist and anti-clenbuterol antisera, 
respectively. The latter assay was advantageous as no sample clean-up step 
was required.
An EIA kit with a hydroxyclenbuterol-alkaline phosphatase enzyme 
conjugate and an anti-clenbuterol antiserum (produced as described by 
Yamamoto and Iwata [84]) was used to measure clenbuterol [91] and 
salbutamol [26] in urine and tissues, respectively. An EIA procedure which 
contained an anti-salbutamol antiserum was developed and described by 
Degand et al. [92]. The antiserum showed principal cross-reactivities relative
to salbutamol (100%) of 115% (clenbuterol), 65% (mabuterol), 31% 
(terbutaline) and 13 % (cimaterol), and the procedure required mimimal sample 
clean-up step and could be used to determine conjugated residues qualitatively 
without a prior hydrolysis step. A novel and rapid approach, developed by 
Ploum et al. [93], was the use of test-strip enzyme immunoassays for the 
direct detection of clenbuterol in urine. The antiserum was prepared as 
described previously by Yamamoto and Iwata [84] and the clenbuterol 
conjugate was clenbuterol horseradish peroxidase. Indication of clenbuterol 
presence, down to 5 ng/ml, was achieved visually, by the appearance of a blue 
colour on the strip.
1.5 .4  Mass Spectrometric Detection
Mass spectrometric (MS) detection, above all other techniques, provides 
unequivocal identification of drugs and metabolites. With respect to (3- 
agonists, the EC has stated that for confirmatory analysis of veterinary drug 
residues, identification of the analyte must be based on at least four 
characteristic fragment ions. To satisfy this criterion it may be necessary to 
combine the data from two MS ionisation techniques, for example electron 
impact (El) and chemical ionisation (Cl) mass spectrometry. In the El mode, 
the (derivatised) /3-agonist molecule is volatilised and bombarded by energetic 
electrons, to produce a protonated molecular ion (M+). In the Cl mode, a
reactant gas (e.g. ammonia) is bombarded with electrons to become ionised 
and collides with the /3-agonist molecule thereby ionising it. The spectrum is 
then scanned for molecular ion and fragment ions, after which the MS may be 
set to monitor the most abundant ions (selected ion monitoring; SIM). The 
peak area measured is proportional to the concentration of analyte.
A prerequisite of 0-agonist analysis by GC-MS is the derivatisation of 
the polar groups (hydroxyls, amino) on the molecule. The silyl derivatives are 
most commonly used; a typical silylation procedure was described by Fuerst 
et al. [35] whereby sample extracts containing clenbuterol were treated with 
hexamethyldisilazane (HMDS) in acetonitrile at 30°C. Garcia-Regueiro et al 
extracted salbutamol, using the method of Fuerst et al. [35], and clenbuterol 
from urine by adsorption SPE to produce extracts for GC-MS. The compounds 
were derivatised with bis(trimethylsilyl)trifluoracetamide and separated on a 
capillary column (100 jum). Detection limits of 1.5 ng/ml in urine were 
reported [94]. Girault and Fourtillan found that trimethylsilyl (TMS) 
derivatives were problematic; the derivatisation step resulted in low sensitivity 
and poor reproducibility and the O-TMS derivative was prone to hydrolysis.
They proposed the use of a dipentafluoropropionyl derivative [14]. The 
clenbuterol perfluoracyl derivative was scanned in the Cl mode and the ion at 
m/z 368 was monitored resulting in detection limits as low as 10 pg/g in tissue 
samples. Several authors have reported the use of two derivatives and two 
detection modes for a more reliable confirmation. Montrade and co-workers
described a procedure applicable to thirteen /3-agonists in urine samples [13]. 
The extracted analytes were derivatised to either their TMS or cyclic-2- 
dimethylsilamorpholine (DMS) derivative, van Rhijn et al. carried out similar 
studies on clenbuterol [95]. This paper described the application of TMS and 
DMS derivatives for the identification of clenbuterol from urine extracts. The 
derivatives were ionised in both El and Cl modes, and the combination gave 
high-intensity diagnostic ions; m/z 86 for both derivatives in the El mode and 
m/z 349 and 351 (TMS derivative) and 391 and 393 (DMS derivative) in the 
Cl mode. Dumasia et al. [19] carried out a multicomponent analysis 
procedure based also on the use of the TMS and DMS derivatives of ¡3- 
agonists using the El mode. The spectra of the TMS derivative showed a base 
peak at m/z 86 (tertiary butyl amino compounds) or 72 (isopropylamine 
compounds). For the cyclic DMS derivatives, the molecular ion peak was 
dominant at m/z 346, as well as two fragment ions at (M-15)+ and (M-43 or
57)+ for the loss of the isopropyl or t-butyl groups, respectively. Boronic acid 
derivatives have also been used to improve the abundance of high mass ions. 
Blanchflower et al. scanned a methylboronic acid derivative of clenbuterol in 
the El mode [32]. The resulting spectra showed three prominant peaks (m/z 
243, 285 and 300), and using SIM, levels of clenbuterol in urine extracts was 
determined. In the procedure of Polettini et al. [38], a comparative study of 
different derivatising reagents for clenbuterol was carried out. The TMS 
derivative showed a major response at m/z =  86, but limited abundance for
all other ions. The trifluoroacetic anhydride (TFAA) derivative led to the 
formation of three or more different products, resulting in spectra difficult to 
interpret. The boronic acid derivatives (phenylboronic acid and 1- 
butaneboronic acid) showed the most abundant ions in the high mass range (at 
m/z 243, 327, 342 and at 243, 347, 362, respectively). The 1-butaneboronic 
acid derivative was chosen as optimum for the further development of a GC- 
MS method for clenbuterol (limit of detection, 0.5 ppb).
For additional information and improved confirmation of /3-agonists by 
scanning daughter ions, GC-tandem MS (GC-MS-MS) has been used [27, 73]. 
A recent development to provide complementary results from GC-MS analysis 
is cryotrapping GC-fourier transform-infra-red spectrometry [96]. Sample 
extracts are derivatised as for GC-MS and the spectra obtained are compared 
to standards for positive identification.
Coupling of liquid chromatography with mass spectrometry (LC-MS or 
LC-MS-MS) has been more difficult due to the need to remove the liquid 
mobile phase prior to entering the MS. However, the advantage of this type 
of determination is that its more suited to polar compounds and hence 
derivatisation procedures are not necessary. Thermospray LC-MS was 
described by Blanchflower and Kennedy [97] for the identification of 
clenbuterol; the m/z 277 fragment ion was monitored (by SIM) in urine 
extracts. Thermospray LC-MS was also suitable for measuring the sulphate 
ester of salbutamol which shows a prominant peak at the m/z 318 ion [21].
Thermospray LC-MS-MS was used to monitor seven 0-agonists [98]; the 
compounds all exhibited the loss of 74 mass units from the molecular ion or 
from prominant fragment ions, thought to be due to the loss o f water and 
methylpropene. A recent development, electrospray ionisation MS, has been 
used to monitor various 0-agonists in aqueous-based standards [15] and for 
clenbuterol in urine extracts [99].
1.6 CONCLUSIONS
0-agonists are relatively polar compounds which can be extracted from 
biological matrices using the more conventional solvent extraction procedures 
or by some form of column chromatography (SPE, IAC). Liver or eye are 
the preferred sample types to monitor illegal usage, but for monitoring levels 
following therapeutic use plasma or urine may be analysed. For tissue 
samples procedures are required to homogenise the sample, followed by 
digestion and extraction of the compound(s).
As clenbuterol has been the most effective repartitioning agent, the bulk 
of the literature has reported determination procedures for its analysis in 
various biological samples. However, with the introduction as growth 
enhancing agents of other compounds in this class, such as salbutamol and 
cimaterol, and the possibility of new chemically-designed 0-agonists, multi­
residue methods are now required. The most effective means of extracting 0- 
agonists of both groups (i.e. aniline-type and the more hydrophilic phenolic- 
type) is achieved through the use of IAC or "mixed phase" SPE cartridges. 
The main criterion for the selection of a detection system for illegal 0-agonist 
use is sensitivity. The two most used techniques have been immunoassay and 
GC-MS. The main advantages of the former technique have been high 
sensitivity and specificity for the test analyte. The vast majority of the 
published immunoassay procedures detect the analytes below 1 ppb.
Procedures based on GC-MS detection reach the sensitivity of immunoassay 
but usually require larger sample sizes (e.g. 5-10 g liver). This technique can 
provide unequivocal confirmation of the jQ-agonist(s). The procedure adopted 
by Montrade et al. [13], for instance, satisfies the EC criteria and allows for 
identification of thirteen /3-agonists in urine extracts at the low ppb level. LC- 
MS has great potential to become a confirmation technique in the field of /3- 
agonists due to its applicability to polar analytes. However, as yet, it has not 
challenged GC-MS in terms of sensitivity.
The most active phase of /3-agonist research for human therapeutic use 
seems to be past, as selective and effective compounds are now readily 
available for asthma or other bronchial diseases. /3-agonists are still being 
administered illicitly as feed additives in animal production and hence 
development of analytical procedures for their detection must continue. The 
reported cases of intoxication in humans following consumption of clenbuterol- 
incurred liver serves as a strong reminder of such abuse [100, 101]. The 
development of suitable methodology with the required sensitivity and 
specificity will help to ensure the safety of edible tissues and protect the health 
of the consumer.
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CHAPTER 2
VOLTAMMETRIC STUDY OF SELECTED /3-AGONISTS AT 
UNMODIFIED AND NAFION-MODIFIED ELECTRODES WITH 
APPLICATION TO THE ANALYSIS OF REAL SAMPLES
2.1 INTRODUCTION
As discussed in chapter 1 (section 1.5.2), the electrochemical approach 
to the analysis of /3-agonists is highly advantageous due to the presence of 
oxidisable substituents (amino, hydroxyl) on the aromatic ring. The primary 
electrode reaction is the oxidation of the hydroxyl moietie(s), the mechanism 
involving a one electron/one proton process. In the case of the catechol /3- 
agonists (e.g. isoprenaline, rimiterol), the highly reactive o-quinone is formed. 
Aniline-type /3-agonists, containing an oxidisable amino group on the aromatic 
ring, are also readily oxidised by a suitable electrode. The secondary amino 
group on the aliphatic part of the molecule also becomes electroactive when 
deprotonated; for the electrooxidation of methadone at a carbon paste 
electrode (CPE), the amino group becomes electroactive at pH values >  5 
[1]. Carbon-based electrodes have been the most suitable for oxidation of 
these moieties and many authors have used them to investigate the 
electrochemical behaviour of selected /3-agonists. Clenbuterol and mabuterol, 
two stucturally-similar /3-agonists, were oxidised irreversibly at high positive 
potentials (+ 0 .75  V vs the saturated calomel electrode (SCE)) at both glassy 
carbon electrodes (GCEs) and CPEs [2]. The large positive potentials 
required were due to the electrophilic substituents (Cl, CF3) on the aromatic 
ring. The irreversible oxidation of the compounds, i.e. absence of reductive 
waves on the reverse scan, is a consequence of a chemical follow-up reaction
of the oxidation products. This was supported by the appearance of small 
reduction/oxidation waves in subsequent scans at considerably lower positive 
or negative potentials at the carbon electrodes. The compounds and their 
products adsorbed on the electrode surface causing inhibition of the current 
response. This was remedied by addition of 30-40% acetonitrile or by using 
an electrochemical cleaning step i.e. holding the potential at -1.5 V for 5 min. 
From this study the authors then developed a sensitive HPLC-ED method for 
the separation and detection of the two compounds in plasma extracts at the 
low ppb level. Hooijerink et al. developed a similar HPLC-ED method for 
the detection of clenbuterol only, using a GCE set at a potential of +1.25 V 
vs the Ag/AgCl reference electrode [3]. The detector signal was found to 
deteriorate due to the adsorption of oxidation products and/or matrix 
components present in the urine extracts. This led to the development of an 
electrochemical cleaning procedure; oxidation of the electrode at high positive 
potentials. The oxidative voltammetric behaviour of salbutamol at the GCE 
was also studied using cyclic voltammetry (CV) and differential pulse 
voltammetry (DPV) [4]. A pH study (half wave potential (EP/2) vs pH) using 
CV revealed that the oxidation of the compound was strongly influenced by 
pH. The phenolic hydroxyl group oxidation gave rise to a single peak in the 
pH range studied. The peak shifted towards negative potentials as the pH 
increased in such a way that two different lines with different slopes were 
observed. The two lines intersected at pH 9.0 which is the expected pKj, value
of salbutamol [5]. Coulometric analysis of the compound showed that two 
electrons were involved in the oxidation process. The compound was 
subsequently determined in tablet formulations by DPV (at optimum pH of 
5.0) giving rise to a peak at +0.75 V vs the SCE reference electrode. Tan 
et al. carried out a hydrodynamic study (i.e. profiles of current vs potential) 
for salbutamol and internal standard, fenoterol at the GCE [6]. An applied 
potential of +0 .60  V was required to initiate an electrochemical response for 
salbutamol whereas for fenoterol a response was initiated at considerably 
lower potentials. Furthermore, the detection limit for fenoterol was found to 
be lower due to a larger signal being generated by the oxidation of the three 
hydroxyl groups. Sagar et al. developed HPLC-ED methods for phenolic ¡3- 
agonists (salbutamol, terbutaline) using a micro carbon fibre electrode [7-9]. 
Hydrodynamic studies for salbutamol [7, 9] showed that the optimum response 
occurred at very high positive potentials ( +1.3  V vs the Ag/Ag3P 0 4 reference 
electrode). The carbon fibre electrode, when compared to the macro-GCE, 
was more advantageous both in terms of lower detection limits (1 ng/ml 
compared to 3 ng/ml) and a less troublesome electrochemical cleaning 
procedure. For the purposes of understanding the processes occurring at the 
electrode surfaces, the use of a CPE is particularly advantageous. The 
benefits gained from using CPEs, i.e. ease and speed of fabrication and low 
background currents, have been previously demonstrated for methadone 
electrooxidation [1]. Moreover this present work shows that CPE’s may be
more suitable than GCE’s for electrochemical studies involving /3-agonists due 
to their greater discriminating power for secondary processes. The 
electrochemical response of the CPE was investigated for three selected /3- 
agonists possessing catechol (salbutamol) or resorcinol (metaproterenol, 
fenoterol) ring structures.
To understand the electrochemical process occurring on carbon paste 
electrodes, both pH and scan rate studies were carried out. The regeneration 
of the carbon paste activity is essential for reproducible analyte response. 
Loss of electrode activity has been attributed to adsorption of reaction 
products, of the analyte itself or other electroactive organic surfactants. Use 
of high anodic potential activation procedures as suggested by Adams and co­
workers [10], and effectively demonstrated by Tunon and co-workers [1], 
results in a very reproducible response with relative standard deviations of less 
than 1 %. For this work, electrochemical pretreatment steps were optimised 
for the three compounds studied.
Chemically-modified electrodes have received a great deal of attention 
in recent years. By concentrating the analyte in the modified layer of the 
electrode, voltammetric determinations can be greatly improved with respect 
to sensitivity and selectivity. Modification of the electrode with 
electrocatalytic moieties or specially functionalized polymers provides 
conventional electrochemical electrodes with a significant functional 
enhancement for analytical applications. One such polymer, i.e. Nafion,
possesses almost ideal properties for preparation of chemically modified 
electrodes. Nafion is chemically inert, non-electroactive, hydrophilic, 
thermally stable and insoluble in water [11]. Studies by Martin’s group [11] 
and [12], have shown that the polymer’s sulphonated (S03 ) moiety shows a 
remarkably high affinity for hydrophobic cations. This has led to the 
development of various carbon-based electrodes modified with the Nafion 
polymer.
The Nafion-modified glassy carbon electrode (NMGCE) has been used 
in flow analysis for the determination of cationic drugs and neurotransmittors 
[13, 14]. Results show that Nafion favours cations considerably over neutral 
species while exhibiting a shielding effect for anions. Further modifications 
of the electrode has resulted in the combination of Nafion with other materials 
such as mercury thin films [15], platinum particles [16], methylene blue dye 
[17] and solvents (for example, tributylphosphate) [18]. A Nafion-modified 
graphite electrode incorporating viologens has been developed for catalytic 
purposes [19]. A recent development is the use of a polyaniline-Nafion thin 
film on a platinum electrode. Polyaniline contains oxidisable groups which 
form positive charge sites on electrooxidation. Current flows if anionic 
species "move into" the polymer and counterbalance the positive charge. 
Nafion, containing negatively-charged S 0 3' groups, can take on this role, and 
together with the polyaniline, attract positively-charged groups like alkali and 
alkaline earth metal ions [20]. Nafion-modified carbon fibre
ultramicroelectrodes have been applied to the analysis of neurotransmitters and 
metal ions [21, 22]. A recent article by Litong et al. reported a 
chronopotentiometric stripping analysis method for adenosine with a NMGCE 
[23]. Gao et al. reported the use of a Nafion-l,10-phenanthroline-modified 
CPE for the determination of Fe(II) [24]. The purpose of the Nafion was two­
fold in this application: firstly to immobilise the complexing agent on the 
electrode surface, and secondly to act as an ion-exchanger for the positively- 
charged iron complex. The design of the electrode is quite different to the 
Nafion-modified CPE used for /3-agonist accumulation. In the paper of Gao 
et al., the Nafion was incorporated into the graphite-nujol paste mixture. For 
the fabrication of the electrode described in this present study, an aliquot of 
Nafion solution was simply added to the surface of a prepared CPE. A thin 
film, formed after drying, was sufficient to act as an ion-exchanger for various 
/3-agonists at optimum pH and Nafion film conditions.
2.2 EXPERIMENTAL
2.2.1 Reagents and materials
A Britton-Robinson (BR) buffer solution was prepared containing 11.48 
ml acetic acid (99.7%), 13.5 ml phosphoric acid (85 %) and 12.44 g boric acid 
per litre. The pH (range varying from 2 to 12) was adjusted using 2 M 
sodium hydroxide. Carbon paste was prepared containing 5 g carbon (Spectro 
pure grade, Fluka Chemical Co.) and 1.8 ml Nujol oil. Lauryl sulphate, 
Triton-X, fenoterol hydrobromide, metaproterenol hemisulphate, salbutamol 
and isoproterenol were purchased from Sigma (St.Louis, MO). L(-)- 
epinephrine was purchased from Janssen Chemica (Beere, Belgium). 
Terbutaline was a gift from The National Food Centre, Ireland. The 
pharmaceutical preparation (Berotec) was prepared by Boehringer Ingelheim, 
(Barcelona). All standard solutions were prepared using deionised water 
(obtained by passing distilled water through a Milli-Q water purification 
system) and stored in the dark at 5°C. Chemicals obtained from Aldrich 
Chemicals were cholic acid (Milwaukee, USA), Amberlite-XAD-2 (Steinheim, 
Germany) and Nafion (Gillingham, UK). Dilutions of the Nafion stock 
solution were prepared using water: isopropanol (1:1). Asolectin soyabean 
(phospholipids) was received from Fluka Biochemika (Switzerland), and 
silicon OV17 was purchased from Merck (Darmstadt, Germany). The
extraction solvent mixture consisted of ethyl acetate (Farmitalia Earlo Erba, 
Milan) and amyl alcohol (Panreac, Barcelona) (9:1).
2.2.2 Apparatus
The experiments were carried out in an all-glass cell designed for a 
three-electrode potentiostatic circuit. Cyclic voltammetric experiments were 
carried out using a VA Scanner E612 and VA detector E611 (both Metrohm) 
coupled to a Graphtec WX4421 recorder. Differential pulse voltammetric 
experiments were carried out using a Model 663-VA stand (Metrohm) 
equipped with a rotating carbon paste disc electrode (18 mm2) and coupled to 
a Model 626 Polarecord (Metrohm). The reference electrode was a Ag/AgCl 
electrode, whereas the counter electrode was a platinum electrode.
2.2.3 Methods
2 .2.3.1 Cyclic voltammetry at carbon paste electrodes
Studies on the effect of pH, using BR buffer pH 2-12, were carried out 
at concentrations of lxlO'4 M (salbutamol) and lxlO'5 M (fenoterol and 
metaproterenol). Scan rate studies, electrochemical activation procedures and 
calibration curves were carried out in the optimum pH. Selected modifying
compounds were evaluated for their capacity to promote an adsorption-type 
process for salbutamol and fenoterol. The modifier was either added to the 
electrolyte solution (cholic acid, lauryl sulphate, Triton X), incorporated into 
the carbon paste (silicon OV17, phospholipids, Amberlite XAD-2) or applied 
in the form of a film on the electrode surface (Nafion).
2.2.3.2 Differential pulse voltammetry at Nafion-modified electrodes
The Nafion-modified electrode was prepared by pipetting 0.01 ml of an 
appropriate concentration of Nafion solution onto the surface of a previously 
prepared CPE. The resulting film was air-dried using a domestic hair-dryer. 
All stripping analyses were carried out in 20 ml BR buffer, pH 2.0. In 
operation, the CPE was immersed in the buffer solution and rotated at a 
constant speed (accumulation times typically 10-60 s, depending on the 
compound concentration) with electrolysis at 0 V. After a 5 s rest period, the 
compound was removed by stripping anodically from 0 V to + 1 .2  V and the 
peak current measured.
2.2.3.3 Analysis o f a pharmaceutical preparation
The pharmaceutical preparation was diluted 1: 500 with deionised water 
and a 0.05 ml aliquot was injected into the cell. 0.05 ml aliquots of fenoterol 
solution (2x1 O'5 M) were added and a 30 s accumulation time was employed.
2.2 .3 .4  Extraction methodology
Urine and serum samples obtained from healthy individuals, were 
stored frozen until assay. After thawing, 5 ml aliquots of urine were fortified 
with an appropriate fenoterol concentration and 2.0 ml of 0.2 M sodium 
hydroxide solution was added. After vortexing, 20 ml of solvent mixture was 
added and the flask shaken by hand for 7 min. The layers were then allowed 
to separate for 15 min. 18 ml of the upper organic layer was removed using 
a glass pipette, evaporated to dryness under a stream of nitrogen at 70°C, and 
redissolved in 2 ml BR buffer, pH 3.0. Differential pulse voltammetry at a 
Nafion-modified electrode was undertaken as described in section 2.2.3.2  
using an accumulation time of 45 s.
For serum, a similar procedure was adopted, but using only 1.0 ml 
aliquots of sample and appropriately-reduced volumes of extraction solvent (10 
ml) and sodium hydroxide (1 ml) solutions. In this case, for improved
sensitivity, the extract was injected into a reduced volume of BR buffer (10 
ml).
2.3 RESULTS AND DISCUSSION
2.3.1 Electrochemical behaviour at bare carbon paste electrodes
The cyclic voltammetric behaviour of salbutamol, fenoterol and 
metaproterenol at bare carbon paste electrodes in BR buffer, pH 8.0, is shown 
in Figure 2.1. The electrochemical behaviour of the three compounds at these 
electrodes over the pH range 2-12 in all cases yields one main irreversible 
oxidation process, which shifts towards more negative potentials as the pH 
increases. The presence of a very distinct secondary process was also 
observed for salbutamol. In the case of fenoterol and metaproterenol, this 
secondary process was also observed but was less distinct and appeared only 
in the pH range 6-10. For salbutamol this process appears in the pH range 6- 
12 and becomes more pronounced as the pH increases.
Figure 2.2 shows the relationship between half-peak potential and pH 
for the two processes of salbutamol at bare CPEs. Linearity for the first 
process was observed in the pH range 1-11, giving a negative slope of 50.7
Figure 2.1
Ep (V) vs SCE
Cyclic voltammograms of (a) salbutamol (concentration 
lxlO'4 M), (b) fenoterol and (c) metaproterenol (concentration 
lxlO'5 M) at carbon paste electrodes (pH=8.0, Scan rate 70 
mVs'1, background scan shown below each compound.).
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PH
Figure 2.2 The relationship between half-peak potential and pH in cyclic
voltammetry for lx l  O'4 M salbutamol (■) and lx l O'5 M 
fenoterol (A) at bare carbon paste electrodes (Scan rate=70 
mVs'1. — indicates main process, — indicates secondary 
process.)
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mV per pH unit. For the second process linearity was observed in the pH 
range 6-8, giving a negative slope of 60.0 mV per pH unit. The main 
process is most likely due to oxidation of the phenolic hydroxyl group. This 
type of process can be observed in both acid and basic media. Amino groups 
can be oxidised only in the non-protonated form and at higher potentials than 
the hydroxyl aromatic group, i.e. amino groups are not electroactive in acidic 
media. For example, no process for the amino group in methadone was 
observed at pH <  5 )[1]. Hence the first process can only be assigned to the 
oxidation of the hydroxyl group and the second process, which cannot be 
observed in acidic media, is due to the amino group oxidation. A break in the 
Ep/2 v s  pH plot for the main process appears between 9.5-10.5, which is in the 
region close to the value reported by other workers [4, 5]. This break, 
however, is not as distinct as that exhibited at a glassy carbon electrode [4], 
and may be due to some interaction of the compound with the pasting 
material. The pKa value, determined from the intersection of the two lines of 
the secondary process was, however, more distinct indicating a pKa value of 
9.3. It is interesting to note that this secondary process was not observed at 
the glassy carbon electrode, indicating the greater discriminating power of the 
CPE for electrode processes occurring at similar potentials.
Figure 2.2 also represents the relationship of half-peak potential and pH 
for fenoterol. Linearity for the main process of fenoterol was observed in the 
pH range 1-10, giving a slope -59.2 mV per pH unit. The lower potential
required to oxidise fenoterol compared to salbutamol is due to the nature of 
the hydroxyl substituents in the molecule. Coulometric studies aimed at 
finding the number of electrons involved in the processes proved fruitless 
owing to adsorption effects. Both fenoterol and metaproterenol are likely to 
exhibit several electron transfer reactions due to the hydroxyl groups in the 
structure. In the case of metaproterenol (results not shown), linearity was 
observed in the pH range 2-6, giving a slope of -60 mV per pH unit. A 
change in the slope occurs after pH 6, and at pH 10 the process is independent 
of pH. The presence of small reduction waves, which move to more negative 
potentials as the pH increased, was seen for salbutamol and fenoterol and may 
be due to products formed after oxidation. Such behaviour was reported also 
for the oxidation of other related compounds, i.e. clenbuterol and mabuterol, 
at CPE’s [2], The relationship of peak current with pH for salbutamol showed 
a decrease in current for the first process as the pH increases, after which the 
second process appears and subsequently the current for this process increases 
with the pH. A similar behaviour was observed for fenoterol. For 
metaproterenol, the peak current decreased with increasing pH. The optimum 
pH for further study, based on obtaining a good signal coupled with adequate 
separation from the background discharge, was in the range 4-5 for all the 
compounds studied.
Scan rate studies were then carried out to assess whether the processes 
at carbon paste electrodes were under diffusion or adsorption control. Table
2.1 gives a summary of results, indicating the concentrations tested, the 
relationship of peak current with scan rate/square root of scan rate, and 
whether the process was diffusion or adsorption controlled. From the results 
one can see that for all three compounds, at high concentrations, a diffusion- 
controlled process occurs. However, at low concentrations, close to the limit 
of detection of the technique, an adsorption process was observed for both 
salbutamol and metaproterenol while for fenoterol a diffusion process was 
found at low concentrations.
Electrode pretreatment procedures based on activation at high anodic 
potentials were then developed for the three compounds. For salbutamol 
analysis, the electrode was kept in a quiescent solution for 30 s under 
electrolysis at +1.55 V. The electrolysis was then switched off and the 
solution stirred for 15 s. For fenoterol and metaproterenol the activation 
potential used was lower, i.e. +1.3  V, and the activation and stirring times 
were 20 s and 30 s, respectively. Using such activation procedures, relative 
standard deviations of <  0.5% (n =  5) were achieved. Using the activation 
procedure, calibration ranges were established for the three compounds. For 
salbutamol, a linear response was obtained in BR buffer, pH 4.0, in the range 
2.5xl0'6 to 4.75xl0'5 M according to the following equation:
ip [nA] =  1.37xlO+7 .C [M ] -1.46 (n=10, r=0.9994)
COMPOUND pH CONCENTRATION
(M)
RANGE
(mVs-1)
EQUATION PROCESS
CONTROL
Salbutamol 4.0
2x10 s 2-90 ip/nA=0.83 v+8.99 
r=0.999n=ll
Adsorption
lxlO'3 2-100 ip/nA= 19.60 v1/2+ 9.29 
r=0.999n=ll
Diffusion
Fenoterol 5.0
3.3x1 O'7 2-40 ip /nA= 4.58 v in -  2.29 
r=0.998 n=6
Diffusion
lxlO5 2-90 ip /nA= 74.23 vw- 36.61 
r=0.998 n=9
Diffusion
Metaproterenol 5.0
5xl0'7 2-100 ip/nA= 0.23 v -36.61 
r=0.998 n=8
Adsorption
5x106 2-100 ip/nA= 15.16 vlfl+ 8.36 
r=0.998 n=8
Diffusion
Table 2.1 Characterisation of the rate-controlling step for the selected 
phenolic p-agonists using cyclic voltammetry at bare carbon paste 
electrodes.
For fenoterol a linear response was established in acetate buffer pH 5.0, in the 
range 5.0xl0'8 to 1.6xl0'6 M according to the equation:
ip [nA ]=6.01xl0+7 .C [M ] +2.28 (n= 9, r=0.9994)
Linearity for metaproterenol was achieved also in acetate buffer, pH 5.0, in 
the range 4.0xl0"7 to 4.25xl0'5 M giving the following equation:
ip [nA] =  1 .71xl0+7 .C [M ] +8 .00  (n=10, r =0.9991)
2.3.2 Electrochemical studies at a Nafion-modified carbon paste electrode
(NMCPE)
None of the modifiers tested, with the exception of lauryl sulphate and 
Nafion, showed higher faradaic currents than those achieved at a bare CPE. 
In some cases (in particular with cholic acid, Amberlite XAD-2 and Triton X), 
very high capacitative currents were recorded. Lauryl sulphate gave almost 
a three-fold increase in peak current for fenoterol (using 2x1 O'4 M lauryl 
sulphate), but an accumulation process did not occur with time. Results 
obtained from using a Nafion-modified electrode for both salbutamol and 
fenoterol showed large increases in peak current as the accumulation time 
increased. Differential pulse voltammetry was performed to obtain 
accumulation curves for the compounds and hence to ascertain their linear 
range. Moreover, cyclic voltammetry with the modified electrode permitted 
determination of the rate-controlling step within the Nafion layer itself. The 
remainder of this work concentrated on studying Nafion-modified electrodes 
in more detail.
2.3.2.1 Influence o f  pH
A pH study, using BR buffer of pH 2-8, was used to evaluate the 
accumulation behaviour of the three compounds at Nafion-modified CPE
surfaces (compound concentration 2.5x1 O'7 M, 0.5% Nafion film and 
accumulation time 30 s). Figure 2.3 shows that the best accumulation of all 
three compounds occurred at pH 2.0, and decreased rapidly as the pH is 
increased. Of the three compounds studied, salbutamol showed considerably 
lower peak currents under the same conditions. In conclusion, it appears that 
for optimum analytical conditions, a pH value of 2.0 would be the most 
suitable. However, the effect of the background current, which is more 
pronounced at lower pH values, must also be considered. pH values between 
2.0 and 3.0 are therefore the best compromise for analyte selectivity.
2.3.2.2 Influence o f pulse height. scan rate and deposition potential
The pulse height was varied over the range 10 to 100 mV in optimum 
buffer conditions and a 0.5% Nafion-modified electrode. The analyte peak 
current increased significantly with pulse height up to 50 mV, after which 
further increase in pulse height resulted only in a small increase in peak 
current. Hence a pulse height of 50 mV was used for all further work.
The influence of scan rate on the peak current was studied in the range 
2-25 mVs'1- The optimum scan rate was either 5 or 10 m V s1, both of which 
gave similar peak currents. However, a scan rate of 10 mVs'1 was chosen for 
all further work due to the shorter analysis times achieved. The response of 
the stripping peak at various initial accumulation potentials was also carried
ip
(n
A
)
pH
Figure 2.3 Effect of pH on the accumulation of 2.5x1 O'7 M
concentrations of fenoterol (■), metaproterenol (A) and 
salbutamol (o) at Nafion modified CPE's (0.5%) using a 30 
s preconcentration time using differential pulse voltammetry 
(DPV)(AE=50mV u=10mV s'1).
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out in the range -0.2 V to + 0 .7  V. No real difference in peak current was 
recorded in the range -0.2 V to +0.1 V, but from + 0 .2  V onwards a 
significant decrease in the response was observed. An electrolysis potential 
of 0 V was chosen as the optimum accumulation potential.
2.3.2.3 Accumulation studies
Accumulation studies on an electrode modified with a 0.5% Nafion 
solution were carried out in BR buffer, pH 2.0. Figures 2.4, 2.5 and 2.6 show 
typical accumulation curves of fenoterol, metaproterenol and salbutamol, 
respectively, at various concentration levels. The fenoterol and metaproterenol 
accumulation curves at Nafion-modified electrodes are very similar in nature. 
Fenoterol exhibited a good linear response up to 120 s at 2 .5x108 M, after 
which the slope levelled off. At the 1.0x10'7 M level the linear response was 
observed up to 45 s, and at higher levels of 2.5xl0'7 and 5 .0xl0‘7 M, 
saturation of the electrode response occurred after 30 s. At low levels of 
metaproterenol of 2.5xl0'8 M, a linear signal was observed up to 60 s. A 45 
s preconcentration time may be used for concentration levels of 1.0x1 O'7 and 
2.5xl0"7 M, respectively. For a concentration of 5.0xl0'7 M a linear response 
may be achieved up to 30 s, as with fenoterol. Salbutamol exhibited a much 
better accumulation onto the Nafion membrane as shown in Figure 2.6. For 
the entire concentration range 2.5x10‘8 to 5.0x1 O'7 M, linearity was obtained
(n 
A
)
time (s)
Figure 2.4 Accumulation curves of fenoterol using differential pulse
voltammetry (DPV) with a 0.5% Nafion modified CPE in BR 
buffer, pH 2.0; 2 .5xl0‘8 M (o), l.OxlO'7 M (A), 2.5xlO'7M (+ )  
and 5.0xl0~7M (□ ) (experimental conditions as in figure 2.3)
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ip 
(n
A
)
1000
time (s)
Figure 2.5 Accumulation curves o f metaproterenol in DPV with a 0.5 %
Nafion modified CPE at pH 2.0; 2.5xl0'8 M (o), l.OxlO'7 M 
(A), 2.5x107 M (□ ) and 5.0xl0‘7 M ( ♦ )  (experimental 
conditions as in figure 2.3)
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tíme (s)
Figure 2.6 Accumulation curves o f salbutamol in DPV with a 0.5%
Nafion modified CPE at pH 2.0: 2.5xlO'8M (o) l.OxlO'7 M 
(A), 2.5x10"7 M (■), 5.0xl0'7M ( ♦ )  and l.Ox 10‘7 M (□) 
(experimental conditions as in Figure 2.3)
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up to 180 s. Higher accumulation times of 240 s at low compound 
concentrations resulted in a change of slope of the line. At high levels of 
l.OxlO'6 M a linear response was observed up to 60 s. This means that, due 
to a structural difference in the salbutamol molecule to that of fenoterol and 
metaproterenol, longer accumulation times and higher concentrations may be 
used. However, for the same concentration level and accumulation time the 
peak currents obtained for fenoterol and metaproterenol are almost twice that 
of salbutamol.
2.3.2.4 Cyclic voltammetry
To understand the rate-controlling step of the process at the Nafion 
membrane, scan rate dependency studies were carried out. For both films 
studied (using 0.5% and 2.0% Nafion solutions), the dependence of the peak 
current (ip) on the scan rate (v) was found to be non-linear. When the peak 
current was plotted versus the square root of the scan rate, a linear response 
was recorded for all three compounds, indicative of a diffusion-controlled 
process. The results are summarised in Table 2.2. The main conclusion to 
be drawn from these results is that the rate-controlling process is the diffusion 
of the compounds from one part of the Nafion layer to another.
COMPOUND NAFION
(%)
CONCENTRATION
(M)
RANGE
(mVs'1)
EQUATION PROCESS
CONTROL
Salbutamol
0.5 1x10 s 5-70 ip /nA= 34.90 vin -19.20 
r=0.997 n=8
Diffusion
2.0 lxlO"6 5-50 ip/nA= 51.84 via -2.14 
r=0.995 n=6
Diffusion
Fenoterol
0.5 5xl0'7 5-80 ip/nA= 52.60 vw -41.01 
r=0.999 n=9
Diffusion
2.0 5xl0‘7 5-70 ip/nA= 86.60v1'2 -65.09 
r=0.998 n=8
Diffusion
Metaproterenol
0.5
2.0
5x1 O'7 
5xl0'7
5-90
5-80
ip/nA= 43.29 vw -33.95 
r=0.999 n=8
ip /nA= 55.54 vw -26.69 
r=0.998 n=7
Diffusion
Diffusion
Table 2.2 Characterisation of the rate-controlling step for the selected
phenolic P-agonists using cyclic voltammetry at Nafion-modified 
carbon paste electrodes using pH = 2.0 and a 30 s preconcentration 
time.
2.3.2.5 Medium Exchange
Medium exchange experiments were then carried out, using fenoterol 
as a model for the other compounds, on unmodified and modified carbon paste 
electrodes. At a modified electrode a medium exchange experiment resulted 
in a peak (compound concentration; 2.5xl0'7 M, tacc; 30s) which was 76% in 
height with respect to that of the original (n =  5, CV =  2.8%). 
Incorporating medium exchange and a 30 s stirring step, a peak 57.9% in 
height of the original was obtained (n =  5, CV = 3.1%). No peak was 
recorded after medium exchange using an unmodified surface. These 
experiments demonstrate clearly that a strong attraction exists between this 
class of compound and the Nafion polymer.
2 .3 .2 .6  Response o f  some endogenous neurotransmitters at the NMCPE
Epinephrine and isoproterenol, two naturally-occurring catecholamines 
with hydroxyl groups at positions 3 and 4 on the aromatic ring were also 
evaluated for their electrooxidation at the NMCPE. In a BR buffer pH 2.0, 
both compounds gave rise to a peak at + 0 .62  V (using the optimum 
conditions already described), but no accumulation occurred with time. Figure 
2.7 shows a voltammogram of a mixture of epinephrine (+ 0 .62  V) and 
fenoterol (+ 0 .92  V) at a common concentration of 2.5x10"7 M, showing the
Figure 2.7 Differential pulse voltammograms o f 2.5x1 O'7 M
concentrations of (A) epinephrine and (B) fenoterol using a 
0.5% Nafion electrode in BR buffer, pH 2.0. (pulse height 50 
mV, scan rate 10 mV s'1)
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good selectivity of the voltammetric method.
2.3.3 Application o f the NMCPE to fenoterol determination in real 
samples
2.3.3.1. Effect o f pH  o f  supporting electrolyte
The results obtained in section 2.3.2.1, indicate that a solution of low 
pH favours high accumulation of the phenolic-type /3-agonists. Although BR 
buffer of pH 2.0 gave rise to higher peak current the effect of background 
current became more pronounced at such low pH values. A BR buffer of pH
3.0 combined good analyte response with satisfactory separation from the 
background current and hence was used for all further work.
2.3.3.2 Optimisation o f  Nafion concentration
The effect of increasing the concentration of Nafion at the CPE surface 
was investigated. Figure 2.8 shows the accumulation profile of 5xl0'7 M 
fenoterol on unmodified and modified surfaces. No preconcentration of 
fenoterol occurred with the unmodified electrode. Using Nafion films, 
however, a preconcentration process was observed resulting in large increases 
in current up until 0.5% Nafion. Further increases in Nafion concentration
200
time (s)
F ig u re  2.8 Comparison of the DPV responses o f fenoterol at a bare
carbon paste electrode and at various Nafion-modified CPE's 
for 5.0x1 O'7 M fenoterol in pH 3.0 BR buffer; Unmodified 
CPE ( • ) ;  0.1% Nafion electrode (A); 0.2% Nafion Electrode 
(□); 0.5% Nafion electrode (o); 0.8% Nafion electrode (♦ ) ;  
2.0% Nafion electrode (■). experimental conditions as for 
figure 2.7
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(up to 2.0%) resulted in insignificant increases in peak current, suggesting that
0.5% may be the optimum concentration of Nafion required. Moreover, a 
lower current was obtained for higher % Nafion films at low accumulation 
times, most likely due to resistance of the diffusion of the compound by a 
thicker layer. From this study, two Nafion concentrations (0.5% and 2.0%) 
were selected; accumulation studies, calibration curves and reproducibility 
studies were carried out to investigate whether there is any advantage in using 
thicker films to enhance the accumulation process.
2.3.3.3 Fenoterol accumulation studies
Accumulation curves, on electrodes modified with 0.5% and 2.0% 
Nafion, were carried out at four concentration levels of fenoterol. Figure 2.9 
(0.5% Nafion) shows the preconcentration of the compound with time. This 
Figure demonstrates that at low concentrations of fenoterol (2.5xl0 8 and 
5.0x108 M) there was a linear response up to 90 s after which the slope 
changes (r =  0.998, n =  5 and r =0.999, n = 5 , respectively). For higher 
concentrations, i.e. 1.0x107 and 5.0xl0"7 M, linearity was observed up to 60 
s and 30 s, respectively (r =  0.999, n =  5 and r =  0.999, n =  3, 
respectively). For all the concentrations studied there were non-zero 
intercepts, indicating accumulation of fenoterol during scanning. Accumulation 
studies with 2.0% Nafion films (results not shown) revealed longer linearity
(n
A)
t  a n t  ( s )
F ig u r e  2.9 Accumulation curves of fenoterol obtained with a 0.5%
Nafion electrode using DPV at pH 3.0 and using the same 
experimental conditions as for figure 2.7: 2.5x10‘8 M (©), 
5.0xl0‘8 M (A); l.OxlO'7 M (■) and 5.0xl0'7 M ( ♦ ) .
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(180 s) at low concentrations of 2.5xl0'8 M. For concentrations above this 
level the linear profile was the same as for 0.5 % Nafion. Overall the 
currents obtained using the higher Nafion concentration were greater but only 
by a relatively small amount. Non-zero intercepts were obtained as for 0.5% 
Nafion.
2.3 .3 .4  Calibration curves
For both Nafion concentrations there was good linearity for all 
concentrations studied, up to and including 30 s. Using this preconcentration 
time and a 0.5% Nafion film a calibration curve covering one order of 
magnitude, 5.0x10'8 to 5.0x1 O'7 M, was observed. The following calibration 
equation was obtained:
i/nA =  4 .08xl0+8 C/M +6.61 (n =  9, r =0.9990)
Using the same preconcentration time and a 2.0% Nafion film, a linear 
calibration curve covering one order of magnitude, 2.5xl0'8 to 6 .0 x l0 7 M, 
was observed. The following equation was obtained:
i/nA =  3 .45xl0+8 C/M +3.33 (n =  9, r =  0.9994)
It was possible to measure concentrations of the drug compound below 
2.5xl0'8 M by applying longer accumulation times, but co-adsorption of 
interferences was observed. The limit of detection of fenoterol using a 45 s 
preconcentration time (calculated using a signal-to-noise ratio of 3) was 9xl0'9
2.3.3.5 Reproducibility
The reproducibility of the Nafion-modified electrode was evaluated at 
two concentration levels of fenoterol (l.OxlO 7 Mand 5.0x1 O'7 M); acceptable 
coefficients of variation, for ten consecutive runs, of 2.21 and 5.25% (0.5% 
Nafion film) and 3.52% and 4.95% (2.0% Nafion film) respectively, were 
obtained. The higher variation observed at higher concentrations of compound 
may be due to modification of the electrode surface by a higher proportion of 
adsorption products. A fresh NMCPE was fabricated for each study. The 
electrode may be prepared reproducibly in a reasonably short period of time 
(typically 20 min).
2.3 .3 .6  Choice o f  Nafion concentration for real samples
Apart from the slightly higher faradaic current obtained with a 2.0% 
Nafion film, no real advantages were derived from its use over the 0.5 % film.
Results from cyclic voltammetry (section 2.3.2.4) show that higher capacitance 
currents are present for thicker films. Moreover, other authors have reported 
that thicker films retain a more powerful barrier to the diffusion of the analyte 
[13, 24]. Hence, for these reasons, a 0.5% Nafion film was chosen for 
application to real samples.
2.3.4 Analysis o f fenoterol in real samples
The level of fenoterol determined directly in a commercially available 
pharmaceutical product was 4.78 mg/ml fenoterol hydrobromide (n =  4, CV 
=  3.81 %). This compares reasonably well with the stated level of 5.0 mg/ml. 
At the 95 % confidence level, the value of t (experimental) was less than that 
of t (theoretical) showing that the method has no systematic error.
For biological matrices, fenoterol was added in the following manner; 
urine samples were fortified with fenoterol to achieve final concentrations of 
2.5xlO'7M and 5 .0x l0 ‘7M, and serum samples were fortified with fenoterol 
to achieve final concentrations of l.OxlO'6M and 5.0xl0'6 M. Figure 2.10 
shows typical voltammograms of fenoterol in a serum extract and subsequent 
standard additions. The results of these analyses are summarized in Table 2.3. 
Good recovery was achieved from both sample types.
A paper by Rominger et al. indicates that urine samples containing 
incurred residues of fenoterol (the availability of which were outside the scope
FFigure 2.10 Differential pulse voltammograms o f fenoterol in BR buffer,
pH 3.0 using a 0.5% Nafion electrode and the same 
experimental conditions as figure 2.7: (A) blank serum 
extract, (B) extract containing 5x1 O'6 M fenoterol and (C)-(F) 
additions of 6 (J,l of 1.0x1 O'4 M fenoterol (cell volume 20 ml)
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Sample
Fenoterol added
(M) n
level determined
(M) CV (%)
Average % 
recovery
Urine
2.5xl0‘7 3 2.30xl0'7 11.3 91.8
5.0x1 O'7 3 4.62x1 O'7 2.95 92.4
Serum
1.0x10* 3 8.72xl0'7 3.05 87.2
5.0xl0‘6 3 3.92x1 O'6 6.41 78.3
Table 2.3 Results obtained for fenoterol-fortified urine and serum samples
after using the extraction procedure and differential pulse 
voltammetry (conditions: 0.5% Nafion electrode, pH 3.0, pulse 
height 50 mV, scan rate 10 mV s'1, tacc 45 s ) .
of this project) are almost completely conjugated [25]. To ensure 
determination of total fenoterol (i.e. free and conjugated), a deconjugation 
procedure was recommended. A publication by van Ginkel et al. used sue 
d’helix pomatia juice (enzyme solution) for the hydrolysis of glucuronide and 
sulphate conjugates in urine samples [26]; samples were incubated with 
buffer, pH 5.2 overnight (18 h) at 37°C. Such a procedure may be carried 
out in fenoterol-incurred urine prior to extraction and the free form of the 
compound analysed using the technique developed in this study.
2.4 CONCLUSIONS
The electrochemical behaviour of three /32-agonists on unmodified and 
modified carbon paste electrodes has been reported. The compounds are 
oxidised at high positive potentials on CPE’s (at pH 4.0, salbutamol +0.84  
V, fenoterol +0.78 V, metaproterenol +0.89 V), giving rise to two 
processes. The rate-controlling step is mainly diffusion controlled, although 
adsorption processes are present for salbutamol and metaproterenol in low 
concentrations, close to the limit of detection of the technique.
Application of a thin film of Nafion on the electrode surface allows the 
preconcentration of the three compounds and increases the sensitivity of the 
technique over bare carbon paste electrodes. An ion-exchange mechanism 
between the protonated (positively charged) compounds and the negatively 
charged Nafion membrane is observed in the pH range studied. Enhanced 
signal at low pH values may be explained by a partition equilibrium (Donnan 
equilibrium) which occurs when the Nafion membrane, saturated with protons, 
remains neutral (S03'H +) and the analyte forms an ion-pair with a background 
electrolyte anion. Cyclic voltammetry results show that the oxidation process 
on Nafion films is diffusion-controlled. Such a phenomenon was also reported 
by Hoyer et. al. in relation to metal ions on Nafion-modified glassy carbon 
electrodes [15].
Epinephrine and isoproterenol, two compounds in this class posessing 
an aromatic ring structure with two hydroxyl groups, were also evaluated for 
their ability to adhere to Nafion films. However, results from these 
experiments, using the same conditions described above, showed that both 
compounds did not accumulate with time. A possible explanation for the non­
accumulation for these compounds may be that only substances with an 
aromatic ring which has three carbon atoms between the hydroxyl groups can 
bind to the Nafion film (i.e. the S 03H group). The compounds studied have 
this structural characteristic, whereas epinephrine and isoproterenol, possessing 
only two carbon atoms between the hydroxyl groups, do not. To further 
check on this theory, another /3-agonist, terbutaline, which has this three 
carbon atom difference, was evaluated for its performance on the Nafion film. 
This compound also accumulated with a response similar to that of fenoterol. 
It is postulated therefore, that the Nafion electrode will accumulate those 
compounds with the hydroxyl groups placed three carbon atoms apart on the 
aromatic ring.
The higher affinity of salbutamol to Nafion films is an interesting 
finding. While this compound has three carbon atoms between the hydroxyl 
groups, it differs structurally from fenoterol and metaproterenol in the 
positioning of one hydroxyl group on the aromatic ring and the other hydroxyl 
group as a methanolic side-chain. It was postulated that this difference caused 
higher accumulation of compound without saturating the electrode.
The NMCPE has been used successfully to determine fenoterol in 
complex matrices. Optimum conditions were achieved with a BR buffer, pH
3.0 and a 0.5% Nafion film. Application of the electrode to a pharmaceutical 
preparations was possible after a suitable dilution of the sample was made. 
The solvent extraction procedure, developed for biological samples, proved to 
be selective for fenoterol with good recoveries obtained at the levels tested. 
This extraction procedure may be suitable for other resorcinol-type 0-agonists.
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CHAPTER 3
DEVELOPMENT AND VALIDATION OF CLENBUTEROL 
EXTRACTION FROM LIVER USING MATRIX SOLID PHASE 
DISPERSION (MSPD) WITH DETERMINATION BY IMMUNOASSAY
3.1 INTRODUCTION
The /3-adrenergic agonist, clenbuterol, has been widely (but illegally) 
used in beef production due to its growth enhancing capability when 
administered to animals at multiple concentrations of the therapeutic dose. 
Work by Meyer and Rinke has shown that liver tissue contains detectable 
residues for 2 weeks after withdrawal of clenbuterol from the animals diet [1]. 
Rapid and efficient extraction techniques are essential, therefore, to control 
illegal usage of clenbuterol and to ensure the safety of meat.
Current methodology for the extraction of clenbuterol residues in tissues 
has been extensively reviewed in Chapter 1. To produce a sample extract 
sufficiently purified for a chromatographic or immunological determination, 
the analyst must perform extensive sample homogenisation, solvent extractions 
and column chromatography. In addition to the obvious disadvantage of the 
length of time required to perform these analyses, the methods require the 
excessive use of hazardous organic solvents. Extractions based on solid phase 
extraction (SPE) overcome the problems associated with large solvent usage. 
For this technique a homogenised tissue sample is added to a suitable SPE 
column and the compounds of interest are isolated from the other sample 
components based on interactions with the column polymer phase.
This approach, while it leads to a reduction in the use of organic solvents, 
does not eliminate labour-intensive steps such as sample homogenisation, 
centrifugation and enzyme digestion.
Alternatives to the above approach have been investigated by Barker, 
Long and co-workers at the Louisiana State University, USA. Their initial 
research focussed on finding suitable tissue-adsorbing solid supports which 
could retain the bulk of the sample matrix but expose the test analyte for 
subsequent elution. They first evaluated the performance of diatomaceous 
earth as a tissue dispersant; the sample was mixed with diatomaceous earth to 
obtain a semi-dry column packing material from which drug compounds, e.g. 
benzimidazole anthelmintics [2], were eluted. Further developments, based 
on the same concept, were carried out using octadecylsilane (C18) material as 
the tissue dispersant. The C18 material acts as both a solid support (the silica 
base) and as a tissue solubiliser (the non-polar C18 moieties). Samples which 
are mixed or blended with this material would be expected to disperse in such 
a manner that the more neutral or lipophilic compounds would solubilise in the 
polymer phase. Thus, triglycerides and the less polar ends of phospholipids, 
steroids and other tissue components, would be expected to insert into the 
phase that is bonded to the surface and pores of the silica particles (i.e. the C18 
phase). More polar components would associate through hydrophilic 
interactions with themselves and with the more polar ends of the compounds 
already inserted in the polymer.
Scanning and transmission electron microscopy studies of the uncoated 
and tissue-coated C18 material surface showed that the mechanical blending 
action disrupts the organelle structure within the tissue. This allows the more 
hydrophilic regions of proteins and moderate to polar drugs to extend 
outwards away from the non-polar C18/lipid region. Water also associates 
with these hydrophilic ends. In practice, tissue sample (0.5 g) and C18 
material (2.0 g) are blended, using a mortar and pestle, for between 30 and 
40 seconds. The resulting mixture is packed into a plastic column to a volume 
of 4.5 ml and wash/elution solvents are added to separate the analyte(s) from 
sample components. Figure 3.1. illustrates the structure of a prepared 
column.
Barker and co-workers have published a wide range of extractions 
based on MSPD methodology. In many cases an assay was developed for the 
isolation of a single compound (e.g. ivermectin [3], chloramphenicol [4]). In 
others, the methods were developed to isolate a class of compounds 
(benzimidazoles [5], halogenated pesticides [6]) or several compound classes 
(organophosphates and beta-lactams [5]) from a sample. The versatility of the 
procedure to isolate a wide range of unrelated compounds is best demonstrated 
in reference [5]. Residues (pesticides, anthelmintics and antibiotics in order 
of increasing polarity) were fractionated using an non-polar solvent (hexane), 
a semi-polar solvent (ethyl acetate) or a solvent of high polarity (methanol). 
Extracts were determined by GC-nitrogen phosphorus detection or HPLC
1Syringe barrel 
C18 Tissue blend
Figure 3.1 A  prepared MSPD column.
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-photo diode array detection. A similar procedure was used to extract eight 
sulphonamides from pork tissue [7]. In this case hexane was used as a wash 
solvent and sulphonamides were eluted with dichloromethane. Small 
modifications in the MSPD procedure were reported by Long et al. [8], who 
proposed the addition of activated florisil to the MSPD column to adsorb fats 
and water, and Schenk et al. [3], who introduced a post-MSPD alumina SPE 
step for improved sample clean-up. The tissue disruption and distribution and 
the subsequent elution profile from an MSPD column may be influenced by 
blending the sample in the presence of acids, bases, salts, chelators or other 
modifiers. For example, tetracyclines are obtained in higher recovery by 
incorporating oxalic acid and other chelating agents (such as EDTA) into the 
MSPD column [9, 10]. Thus, the polarity of the target compound may be 
altered by protonation or deprotonation so as to cause a drug or metabolite to 
be retained longer or eluted earlier. MSPD methodology is not reserved 
solely for tissue samples; some publications report MSPD extraction of 
antibiotics [4], benzimidazoles [11] and the herbicide, chlorosulfuron, [12], 
from milk samples. Work at the National Food Centre (Dublin) has extended 
the application of MSPD for sulphonamide analysis through its linkage with 
a TLC determination step to provide a kit method for use in industry [13, 14]. 
Other applications developed by the NFC and associated laboratories have 
been for ivermectin in fish [15] and gestagens in tissue [16]. A general 
summary of the applications of MSPD for a range of analytes, based on their
polarity, is shown in Figure 3.2. This study demonstrates the extension of the 
MSPD method to the extraction of (8-agonists from liver samples. Residues 
extracted by MSPD are normally determined by chromatographic-based 
techniques like HPLC and GC. This is due, mainly, to the multianalyte 
detection capability of these techniques, and also because the detection limits 
required are relatively high (10-100 ppb). To monitor clenbuterol, in the 
context of illegal usage, such detection limits are unsuitable (the MRL for 
clenbuterol set by the UK is 0.5 ppb). Immunoassays are commonly used to 
determine residues of banned substances (e.g. steroids). Coupled with an 
efficient extraction procedure, immunoassay techniques have the capability to 
measure residues as low as 10 ppt [17]. The two immunoassay procedures 
most used in the field of drug residue analysis have been radioimmunoassay 
(RIA) and enzyme immunoassay (EIA).
Radioimmunoassays for the quantitative detection of small molecular 
analytes such as veterinary drugs generally employ tritiated antigens and 
specific antibodies. A fixed amount of radiolabelled antigen is added to the 
sample extract and following competitive binding by an antibody, the bound 
complex is separated (demonstrated in Figure 3.3). The level of radioactivity 
is determined in the bound complex. To quantify the level of unlabelled 
antigen (the analyte) in the sample extract, a calibration curve is prepared 
using a range of standards which compete with the radiolabelled antigen for 
binding to the antibody. Fewer radiolabelled molecules are bound to the
MATRIX SOLID PHASE DISPERSION
F ig u re  3.2
SUITABLE APPLICATIONS
TISSUE/C1a
t
HEXANE
DICHLOROMETHANE
ETHYL ACETATE
ACETONITRILE
METHANOL
WATER
BLEND
ORGANOPHOSPHORUS
PESTICIDES
SULPHONAMIDE
ANTIBIOTICS
CHLORAMPHENICOL
ANTIBIOTIC
BENZ1MIDAZOLE
ANTHELMINTICS
ORGANOCHLORIDE
PESTICIDES
CLENBUTEROUSALBUTAMOL 
PENICILLIN, AMPICILLIN
The extraction of an analyte from an MSPD column depends on 
the selection of an organic solvent o f similar polarity.
-102-
Ag
Ag
F igu re  3.3
+ Ab Atequilibrium
AgAb Ag
+
Ag*Ab Ag*
Bound
fraction
▼
Free
fraction
Principle o f radioimmunoassay: Ag = unlabelled antigen; Ag = 
radiolabelled antigen; Ab = antibody; AgAb = antigen-antibody 
complex.
-103-
antibody as the concentration of the unlabelled antigen increases and 
consequently, a lower signal (i.e. radioactivity) is counted. The resulting 
standard curve between antibody-bound radiolabelled antigen (%) against 
concentration of unlabelled antigen is sigmoid in nature. The procedures 
leading to the production of antiserum have been discussed in Chapter 1 
(section 1.3.3). The antiserum is then tested for titre (a measure of the 
concentration of cross-reacting antibodies in the serum) and specificity (the 
measure of the exclusiveness of cross-reactivity to the analyte(s) of interest). 
In addition to polyclonal antiserum (i.e. antibodies derived from several clones 
of lymphocytes) as described in Chapter 1, monoclonal antiserum (i.e. 
antibodies derived from a single clone of lymphocyte) may be prepared and 
used in the RIA procedure.
The labelling of antigens is generally accomplished by the replacement 
of carbon, hydrogen or iodine with 14C, 3H or 125I, respectively. For RIA 
procedures for the determination of small molecules, however, labelling with 
tritium [3H] is most common as Iodine [125I] is a large molecule which can 
interfere with antibody binding. It is essential for efficient RIA that the 
radiolabelled and unlabelled antigen have equal affinity for the antibody. One 
particular RIA procedure which utilises the [125I] -analyte tracer is that 
described by Rominger et al. for the determination of fenoterol [17]. For 
radioimmunoassay, the antisera is diluted to a concentration where it binds 
with 50% of the selected concentration of radiolabelled antigen. This situation
represents the optimum for competition when the standards or sample extracts 
are introduced into the RIA procedure.
The first RIA procedure, prepared for determination of clenbuterol 
residues (in the context of illegal usage) was developed by Delahaut et al.
[18]. As in other immunoassay procedures (both RIA and EIA), the 
immunogen was prepared by the method of Yamamoto and Iwata [19]. The 
antiserum was specific for clenbuterol with lower cross-reactivity to 
salbutamol, terbutaline and cimaterol (<  10% relative to clenbuterol). Loo 
and co-workers developed a RIA procedure, using a radiolabelled [3H]- 
salbutamol antigen, specific only for salbutamol (but not salbutamol 
conjugates) in plasma extracts [20]. Adam et al. also reported a RIA 
procedure for salbutamol, but using a monoclonal antibody [21]. 
Interestingly, the antibody showed a high cross-reactivity to clenbuterol 
(75 %). Rominger et al. used an RIA procedure which had an antibody cross­
reacting with the different sterioisomers of fenoterol; this compound was 
detected in biological fluid extracts at the sub ppb level [17].
Enzyme-linked immunosorbent assay (ELISA) provides an alternative 
to the RIA procedure and has become the more favoured technique in the field 
of residue analysis. There are advantages in using ELISA over RIA; the 
availability of cheap and commonly available equipment and the absence of 
radiolabelled compounds and scintillation solvents. Figure 3.4 shows different 
types of ELISA’s applied in residue analysis. The choice of enzyme and its
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specific activity are primary considerations in relation to assay sensitivity as 
it will determine the strength of the signal at the assay end-point. Typical 
enzymes used are /3-galactosidase, alkaline phosphatase and peroxidase. The 
enzyme is conjugated to either the antigen or antibody through a lysine amino 
group of the enzyme or, where glycoprotein enzymes such as peroxidase are 
used, through carbohydrate groups.
The first EIA for clenbuterol was developed by Yamamoto and Iwata
[19], a double-antibody and heterogenous immunoassay based on competition 
for binding between clenbuterol and its /3-D-galactosidase-labelled analogue for 
a limited amount of antibody, followed by binding of the enzyme-labelled 
analogue and a second antibody. The activity of the bound enzyme was 
determined fluorometrically after addition of substrate. Degand et al. used an 
EIA procedure with a clenbuterol-horseradish peroxidase (HPO) enzyme 
conjugate to measure clenbuterol in bovine tissues at less than 1 ppb [22]. 
EIA kits containing salbutamol-based enzyme conjugates, salbutamol-4- 
carboxymethylether-HPO [23] or salbutamol hemisuccinate-HPO [24,25] were 
used to determine clenbuterol in urine and tissue samples. Multi-/3-agonist 
EIA kits containing antiserum directed against a number of compounds have 
also been developed [26, 27]. A more rapid approach to /3-agonist testing may 
be achieved using an "on-site" test strip enzyme immunoassay. The antibodies 
were prepared as previously described [19] and the clenbuterol conjugate was 
clenbuterol horseradish peroxidase. Determination of clenbuterol in urine
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samples down to 5 ng/ml, was achieved by the visual appearance of a blue 
colour on the strip [28], In this following study, a competitive double 
antibody ELISA was used to determine clenbuterol after MSPD extraction 
from liver. The ELISA kit contained an anti-immunoglobulin (IgG) antibody, 
immobilised on the surface of the microtiter wells. When the anti-clenbuterol 
antibody, the clenbuterol standard (or sample extracts) and the clenbuterol 
enzyme substrate were added to the wells, two mechanisms occurred; 
competition between the clenbuterol and enzyme-labelled clenbuterol for 
binding to the anti-clenbuterol antibody and binding of this antibody by the 
immobilised anti-IgG antibody. After washing, to remove unbound material, 
a substrate was added to produce a coloured product which was measured 
spectrometrically.
For the work carried out in this study, both RIA and EIA 
(commercially available as kits) were employed to detect clenbuterol in liver 
extracts produced by MSPD. Both techniques report determination limits of 
less than 1 ng clenbuterol per gram of liver.
3.2 EXPERIMENTAL
3.2.1 Reagents and Equipment
Hexane (’extra pure’ grade) and ethanol (absolute) from Merck 
(Darmstadt, Germany), dichloromethane and methanol (’Hypersolv’ grade) 
from BDH (Poole, UK) and double-distilled water were used. Other 
chemicals used were Analar grade from BDH, or equivalent. Clenbuterol 
hydrochloride from Sigma (St. Louis, MO, USA) was used for fortification 
of samples.
Immunoassay kits used for determination of clenbuterol were the 
following: (a) Radioimmunoassay kit, supplied by Laboratoire
d’Hormonologie (Marloie, Belgium) was used for determination of 
clenbuterol. The [3H]-clenbuterol in this kit, with a specific activity of 13 
Ci/mmol (481 GBq/mmol), was used for method optimisation. The 
clenbuterol antiserum in the kit has principal cross-reactivities (relative to 
100% for clenbuterol) of 9% (terbutaline), 7.7% (salbutamol, free base), 
6.8% (salbutamol, sulphate salt), 2.75% (cimaterol) and 0.11% (pirbuterol). 
(b) Enzyme-immunoassay kit supplied by R-Biopharm (Germany) with 
antiserum which had been raised against clenbuterol and had principal cross­
reactivities relative to 100% for clenbuterol of 71% (mabuterol), 11% 
(salbutamol), 6% (terbutaline) and 6% (cimaterol).
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For the radioimmunoassay 0.01 M phosphate buffer (pH 7.0), 
containing 1 g/1 gelatin and 0.1 g/1 thiomersal, was used. Dextran-coated 
charcoal was prepared by adding 2 g activated charcoal (Sigma) and 0.25 g 
dextran T70 (Pharmacia, Uppsala, Sweden) to 500 ml double-distilled water. 
The scintillation cocktail was Cocktail T (BDH). Preparative grade Bondesil 
Cjg (40 jum) packing material, supplied by Analytichem International (Harbor 
City, CA, USA) was used for the extraction procedure. This material was 
prepared by placing it in a plastic syringe barrel (50 ml) and washing 
sequentially with two column volumes each of hexane, dichloromethane and 
methanol and drying by vacuum aspiration [6]. Extraction columns were 
prepared in prewashed plastic syringe barrels (10 ml) and qualitative filter 
paper discs (No. 1, Whatman, Maidstone, UK) were used as frits.
3.2.2 Apparatus
A LKB Wallac 1219 Rackbeta liquid scintillation counter was used to 
count the radioactivity present in extracts from the MSPD procedure. 
Absorbance measurements on samples determined by EIA were carried out 
using a Dynatech Minireader with a 410 nm filter.
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3.2.3 Methods
3.2.3.1 Samples and Sample Preparation
All samples of bovine liver were stored frozen, until assay. Liver 
samples from animals certified as not treated with clenbuterol were 
homogenised for use in fortification studies and for production of liver extract 
to be used in the standard curve.
3.2.3.2 Fortification
The method was optimised by extraction of samples fortified with 193 
Bq [3H]-clenbuterol per 0.5 g tissue. The method was validated by analysis 
of samples fortified with clenbuterol; levels of 0.5, 1.0 and 2.5 ng clenbuterol 
in 10 fi 1 ethanol, were added to 0.5 g tissue prior to extraction. Fortification 
was carried out by pipetting the material on to the surface of the sample and 
leaving for 10 minutes prior to extraction.
3 .2 .3 .3  Extraction
0.5 g liver was weighed into a glass mortar and 10 fA ethanol or an 
appropriate clenbuterol solution added. 2 g of the C18 packing material was 
added to the mortar and blended with the tissue by mixing with a pestle for 40 
seconds. The mixture was removed from the mortar and transferred to a 10 
ml syringe barrel containing two filter paper discs and with a 100 ¡A pipette 
tip attached to its outlet. The syringe barrel was tapped to settle the mixture 
and two filter paper discs were placed on top of the mixture. The mixture 
was compressed to a volume of 4.5 ml with a syringe plunger (from which the 
rubber seal and pointed plastic retainer had been removed). The column was 
washed with 8 ml of hexane and 8 ml of double-distilled water. After each 
wash solvent had flowed through the column, positive pressure was applied to 
the top of the syringe barrel with a pipette bulb to remove surplus solvent. 
8 ml of methanol was then added to the column, the first 1 ml of eluate 
(mainly water) was discarded and the remaining eluate collected. This eluate 
was evaporated to dryness under a stream of nitrogen, at 55°C on a sample 
concentrator, and redissolved in 0.5 ml of ethanol (for RIA procedure) or 1.0 
ml of water (for EIA procedure).
3 .2 .3 .4  Radioimmunoassay procedure
Standard curves (10 to 1000 pg clenbuterol per tube) were prepared 
both with and without tissue extract. The extract-containing curve was 
prepared by the addition of 0.1 ml of a pooled extract of control tissue 
samples to each standard tube. 0.1 ml of sample extracts were assayed, in 
duplicate. The contents of all tubes were evaporated to dryness under a 
stream of nitrogen at 40°C and 0.5 ml of phosphate gelatin buffer was added. 
After vortexing and incubation for 15 minutes at 37°C, 0.1 ml [3H]-clenbuterol 
and 0.1 ml antiserum were added. The tubes were incubated at 37°C for 15 
minutes and overnight at 4°C. 0.5 ml of dextran-coated charcoal suspension 
was added to separate bound from free clenbuterol and the tubes were 
centrifuged at 2000 rpm for 10 minutes. The supernatant was decanted into 
scintillation vials, 10 ml of scintillation cocktail was added and the 
radioactivity counted.
3.2.3.5. Enzyme immunoassay
The following solutions were added to the wells of the microtiter plate; 
0.1 ml of enzyme conjugate, 0.020 ml of standard clenbuterol (0-162 ng/ well) 
or sample extract and 0.1 ml of antiserum. The microtiter plate was 
subsequently vortexed and incubated overnight at 5°C. After emptying and
washing the wells, 0.050 ml aliquots of substrate and chromogen were added 
and the microtiter plate incubated at room temperature for 30 minutes. 
Finally, 0.1 ml of stop solution (1.0 M sulphuric acid) was added and the 
absorbance measured using a 410 nm filter.
3.3 RESULTS AND DISCUSSION
3.3.1 Method optimisation
A range of solvents of differing polarities were evaluated for their 
capacity to elute [3H]-clenbuterol from the MSPD column. 8 ml volumes of 
each solvent were used as such a volume has been found suitable in previous 
studies with the MSPD technique [5, 7]. The [3H]-clenbuterol was not 
removed from the column by non-polar solvents, such as hexane, and was 
only partially removed by solvents of intermediate polarity, such as 
dichloromethane and diethyl ether. Polar solvents, such as methanol, were 
found to give almost complete recovery of added [3H]-clenbuterol. The [3H]- 
clenbuterol was not removed from the column with water. Figure 3.5 shows 
elution profiles for [3H]-clenbuterol from the columns, obtained by counting
0.5 ml fractions of the methanol eluate. Most of the [3H]-clenbuterol is 
recovered in the second to fourth ml of the methanol eluate and the first ml,
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which is mostly water retained from the aqueous wash step, can be 
discarded. A suitable clean-up and extraction procedure was the following: 
the column was washed with 8 ml hexane (to remove non-polar interferences) 
and 8 ml water (to remove polar interferences) prior to elution with 8 ml 
methanol. Using these conditions, recovery of [3H]-clenbuterol in the 
methanol fraction was 101.9% (± 6 .0 % , n =  6).
3.3.2 Method validation by radioimmunoassay
Standard curves for radioimmunoassay were prepared both with and 
without tissue extract. For the extract-containing curves, sufficient 0.5 g 
aliquots of a control liver sample were extracted by the MSPD procedure to 
give a pool of liver extract for the curve. 0.1 g equivalent of control sample 
extract was added to each standard tube. Figure 3.6 shows the standard 
curves (calculated from 8 separate assays) prepared with and without tissue 
extract. Good parallelism between the curves was found, indicating that a 
curve without tissue extract may be used. The value for the control liver 
extract in standard curves without extract was 23.6 pg/tube ( + 3 .4  pg, n =
The inter- and intra-assay variations of the method are shown in Tables
3.1 and 3.2, respectively. Results are presented for radioimmunoassay 
standard curves both with and without tissue extract. Good recovery of
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Figure 3.6 Radioimmunoassay standard curves; □  = with extract; + = without 
extract.
Clenbuterol determined (ng/g)
Clenbuterol  .___ ____________________
added n (a) (b)
(ng/g) ------------------------------------  ----------------------------------
mean ± SD CV (%) mean ± SD CV (%)
1
2
5
6 0.98 ±0.12
6 1.94 ±0 .26
6 4.99 + 0.84
12.3
13.2
16.9
0.93 ±0.18 
1.71 ± 0.32 
3.70 ± 0.60
19.3
18.8
16.1
Inter-assay variation for MSPD/RIA determination of clenbuterol 
in liver; results are calculated on standard curves with (a) and 
without (b) tissue extract.
Clenbuterol
Clenbuterol determined (ng/g)
added
(ng/g)
n (a) (b)
mean ± SD CV (%) mean ± SD CV (%)
1 6 1,16 ± 0.07 5.9 0.91 ± 0.05 4.9
5 6 4.69 ± 0.60 12.7 3.88 ±  0.35 8.9
T ab le  3.2 Intra-assay variation for MSPD/RIA determination o f clenbuterol,
in liver; results are calculated on standard curves with (a) and 
without (b) tissue extract.
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clenbuterol (97%-99%) was achieved for extracts measured against the 
standard curve containing extract (Table 3.1). For extracts measured against 
an external standard curve, good recovery of residue was obtained for 1 ng/g 
(93%) and 2 ng/g (86%), but lower recovery was determined for the 5 ng/g 
(74%) level. This apparent low recovery is due to inaccuracy of the 
radioimmunoassay rather than to losses in the extraction procedure; a 
relatively high non-specific binding (NSB) value occurs in extracts prepared 
by the MSPD procedure and its negative influence on quantitation increases 
with concentration of analyte in the extract. The intra-assay results (Table 
3.2) show acceptable variation within a single assay for samples fortified at 1 
and 5 ng/g.
Overall, high recovery of clenbuterol is obtained from the MSPD 
column and may be determined in a standard curve prepared with or without 
tissue extract addition. Use of a standard curve without tissue extract is 
normally preferred due to the decreased number of tissue samples required to 
be processed by MSPD and, hence, the reduced time and cost of the assay.
3.3.3 Method validation by enzyme immunoassay
Fortified sample extracts containing 1, 2 and 5 ng/g clenbuterol were 
determined by EIA and results are shown in Table 3.3. The clenbuterol 
content in the extracts was measured using a clenbuterol standard curve
without tissue extract and, overall, the estimation of clenbuterol recovery 
(84% -96%) was higher than that obtained by an equivalent RIA measurement 
(74%-93% , see Table 3.1).
3.3.4 Sample analyses
Table 3.4 shows the results for analysis of samples containing incurred 
clenbuterol. The levels determined by the MSPD procedure, using standard 
curves with and without tissue extract, are compared with results obtained by 
a solvent extraction method [29]. This method consists of protease digestion 
of the sample (55 °C for 2 h), multiple extractions with diethyl ether and 
determination of the clenbuterol in the extract by radioimmunoassay. Good 
comparison between the two methods was found. The coefficient of variation 
(CV) for analysis of residue-positive samples by MSPD/RIA was found to be 
10-11% (Table 3.4); This compares well with the solvent extraction method 
for which a CV value of 17.4% was obtained for a quality control sample 
(mean = 0.33 ng/g, SD = 0.058, n =  6).
3.3.5 Limit o f detection
A tentative limit of detection for the MSPD procedure was determined 
by RIA analysis of liver samples free of clenbuterol residue. The mean value
Clenbuterol
added
(ng/g)
n
Clenbuterol determined (ng/g) 
Mean ±  SD CV (%)
T a b le  3.3:
Table 3.4
1 4 0.96 ± 0.23 24.0
2 4 1.96 ± 0.20 10.2
5 4 4.20 ± 0.57 13.6
Inter-assay variation for MSPD/EIA determination of clenbuterol 
in liver.
Clenbuterol determined (ng/g)
Sample Standard method MSPD/RIA (n = 6) MSPD/EIA (n = 4)
~ ( ¡ )  (bj
Mean ±  SD Mean ±  SD Mean ±  SD
A 3.60 3.61 ± 0.35 3.07 ±  0.34 3.20 ± 0.57
B 1.62 1.84 ±0.21 1.84 ±0.19 1.90 ± 0.68
Clenbuterol levels determined in residue-positive liver samples by 
MSPD/ RIA and MSPD/EIA, compared with a standard technique; 
results from MSPD/RIA are calculated on standard curves with (a) 
and without (b) tissue extract.
for these samples was 0.18 ng/g (+. 0.04 ng/g, n =  8), determined in a 
standard curve without tissue extract; the limit of detection, calculated as the 
mean plus 3 times the standard deviation, was 0.30 ng/g. Assay of a much 
larger number of clenbuterol-free samples (for example n =  50 [30]) would 
be required to give a robust limit of detection for the method.
3.4 CONCLUSIONS
The MSPD technique has been developed successfully for application 
to the analysis of clenbuterol in liver samples. Satisfactory results were 
obtained when the determination of residue levels was by radioimmunoassay 
(either with or without tissue extract) and enzyme immunoassay. In the 
former case, the use of a standard curve without tissue extract is preferred 
because of the reduced time and cost of the assay. Recovery of clenbuterol 
from fortified samples was greater than 70% (in most cases around 90%) and 
results for samples containing incurred residues compared well with a solvent 
extraction method [26]. The developed technique offers a simple, rapid 
procedure for assay of clenbuterol in tissue samples. The MSPD technique 
can be applied to assay of residues at levels of 0.5 ppb, or lower, and suitable 
extracts are produced from the technique for determination by immunoassay.
The MSPD method eliminates many of the problems associated with 
classical isolation techniques. The method uses small sample sizes (0.5 g), 
has a minimal number of steps, requires no chemical manipulations (such as 
pH adjustments) and requires low solvent usage (16 ml). Conversely, a 
typical solvent extraction method used requires 5.0 g of sample, 
homogenisation of the sample, protease digestion, a minimum of 30 ml of 
diethyl ether, pH adjustments and multiple extractions. For a typical 
analytical run of 10 to 20 samples, the MSPD procedure takes slightly more
than half the operator time required for a solvent extraction procedure.
The inclusion of incurred liver samples in the study provides a better 
validation of the MSPD method. The bulk of the previously reported MSPD 
methods do not include such data, due mainly to the time and expense 
involved in treating animals. The drawback of reporting methods based only 
on fortified samples is that no account is taken of the form in which the 
residue may be present in the tissue matrix. Hence there may be a different 
degree of extraction between fortified and incurred samples. In the described 
MSPD method for clenbuterol the combination of high analyte recovery and 
good comparability with an alternative procedure for incurred samples, 
suggests that both residue types (i.e. fortified and incurred) are extracted .
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CHAPTER 4
MATRIX SOLID PHASE DISPERSION (MSPD) AS A MULTIRESIDUE 
EXTRACTION PROCEDURE FOR /3-AGONISTS IN BOVINE LIVER 
WITH DETERMINATION BY IMMUNOASSAY
4.1 INTRODUCTION
The work on MSPD described in the previous chapter 
demonstrated the suitability of the technique for the extraction of polar 
compounds. Clenbuterol is not extracted from the MSPD column with non­
polar solvents and is only partially removed with solvents of intermediate 
polarity: the compound elutes fully only in methanol. Other compounds in 
the /3-agonist class, with similar structures and polarity characteristics to 
clenbuterol, would be expected to elute from the column in methanol; aniline- 
type compounds like mabuterol and cimaterol differ only in the type of 
substituents attached to positions 3 and 5 in the aromatic ring and on the 
substituent attached to the iso-propyl group on the aliphatic part of the 
molecule (cimaterol only). Cimaterol, in particular, needs to be monitored, 
as it performs as a very efficient repartitioning agent in a similar way to 
clenbuterol [1]. Salbutamol has also been administered illegally to animals; 
data from Furst et al. indicates widespread use of this substance as a growth 
enhancing agent in beef production [2]. Moreover, because it has a shorter 
half-life than the aniline-type /3-agonists, it would be more difficult to detect. 
Since the above mentioned compounds, as well as new related compounds, are 
frequently detected and identified as growth enhancing agents, it appears 
necessary to move away from monitoring individual compounds and develope, 
as far as possible, multi-residue analysis methods.
Because /3-agonists as a class contain substances of differing chemical 
properties, variable recoveries from multiresidue methods are usually reported. 
Optimisation of the residue extraction procedure for clenbuterol-like /3-agonists 
can result in a reduced recovery for salbutamol-like substances [3-5]. In the 
paper by Leyssens et al. [3], using a combination of sample clean-up 
techniques for liver, reasonable recoveries of mabuterol and clenbuterol were 
achieved (85% and 60% respectively), but the recovery of salbutamol, 
terbutaline and fenoterol was poor (<  35%). The method reported by van 
Ginkel et al. [4], which uses adsorption column solid-phase extraction (SPE) 
and immunoaffinity chromatography, gives rise to better salbutamol recovery 
(40-50%), but overall it was still low compared to the aniline-type compounds 
(60-70%). A recent paper by Montrade et al. which adopted a "mixed phase" 
SPE clean-up of urine samples gave reasonable extractability of thirteen /3- 
agonists, including some phenolic-type compounds (e.g. 65% for ractopamine 
and 59% for fenoterol), but again for salbutamol, metaproterenol, and related 
substances poor recoveries were obtained (<  35 %)[5].
Matrix solid phase dispersion (MSPD) provides an alternative extraction 
methodology for a multi-residue analytical approach to analysis. In this 
extraction method sample matrix components are dispersed over a large 
surface area and, simultaneouly, lipid materials and internal membrane lipids 
associate with the C18 material to essentially unfold the structural components. 
This process allows the more polar compounds (including drug components)
to extend outwards and make them more extractable into organic solvents. 
The majority of MSPD publications report multiresidue extraction procedures, 
mostly of veterinary drugs and pesticides. Components of different classes are 
fractionated from the MSPD column with different solvents depending on their 
polarity. A paper by Barker and co-workers [6] demonstrates this versatility: 
residues of pesticides, anthelmintics and antibiotics were fractionated from the 
MSPD column (containing bovine muscle-C18 blend) with hexane/benzene, 
ethyl acetate and methanol, respectively. Recovery of the components, 
analysed by high performance liquid chromatography, was in most cases 
greater than 70%. For the extension of MSPD methodology to /3-agonist 
determinations, the water wash step used for clenbuterol extraction (see 
Chapter 3) was liable to remove hydrophilic compounds, for example 
salbutamol. This proved to be the case for certain brands of CIg material. An 
alternative option was the linkage of MSPD and SPE, thereby avoiding the 
necessity for a water wash step. Such an approach was also adopted by 
Schenk et al. for the isolation of ivermectin in muscle tissue samples [7]. 
This chapter examines both options (with and without a water wash step), with 
the ultimate aim of developing a robust and sensitive procedure with good 
extraction capability for a variety of /5-agonists in liver tissue.
Procedures which aim to determine phenolic-type /3-agonists must 
provide an additional hydrolysis step to deconjugate residues present in 
biological samples. Compounds with a catechol structure, like rimiterol and
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isoprenaline, are metabolised by an O-methylation reaction which occurs at 
positions 3 and 4 on the aromatic ring (see Figure 4.1). Compounds such as 
salbutamol, with a phenolic ring structure, are usually metabolised to sulphate 
(and to a lesser extent, glucuronide) conjugates. The resorcinol /3-agonists, 
like terbutaline and fenoterol, are also conjugated in this way, but in the case 
of compounds such as clenbuterol and mabuterol sulphate conjugation cannot 
take place. The effect of such conjugation means that the compounds have 
very short half-lives (e.g. 0.02 h for rimiterol in man) and hence are 
eliminated rapidly from the body. For the use of /3-agonists as repartitioning 
agents, drugs with a long half-life are more practical as the active compound 
persists longer in the treated animal. This may explain why compounds like 
clenbuterol (with a half-life of 7 h in man) and cimaterol are often chosen as 
growth enhancing substances in preference to salbutamol, terbutaline etc. 
However there does not always seem to be a direct relationship between 
duration of the effect and the half-life of the drug [8].
Conjugated residues pose particular problems in residue analysis: 
(a) the conjugates may not extract as well as the free compounds due to their 
increased polarity; and (b) the antiserum used in the immunoassay which is 
directed against the free compound may have no (or a lower) cross-reactivity 
to the conjugate. Hydrolysis studies have been carried out with aniline-type 
/3-agonists to confirm that these compounds do not occur as conjugates. For 
clenbuterol-incurred urine samples, the amount of drug found following
(PST)
[glucuronidation] o h h 2c
^OH, —  O U ­
CH,
NH — C —  CH,
F igu re  4.1 Main metabolic pathways for (a) catechol (rimiterol) and (b)
resorcinol (salbutamol) [3-agonists
hydrolysis was not significantly different to that determined without 
hydrolysis. Clenbuterol is excreted mainly as the parent compound (24%), 
mandelic acid metabolite (20%) and the hippuric acid metabolite (19%) and 
O- and N- glucuronide formation accounted for approximately 5% of the 
excreted drug [9, 10]. Similar results were reported for the structurally- 
similar compound, mabuterol [11].
For the phenolic-type /3-agonists, conjugate formation has been 
reported. Two main types of hydrolysis procedures, namely enzyme and acid 
hydrolysis, have been used prior to sample clean-up. Enzyme hydrolysis of 
salbutamol conjugates was carried out in urine and liver homogenate; the 
samples were adjusted to pH 5.0 and incubated with a dilute solution of 
enzyme (glucuronidase/ sulphatase) at 37°C for 16-18 h [4, 5, 12]. The 
method of Montrade et al. [12] is particularly informative in this regard, as 
the authors carried out hydrolysis studies on urine and a number of bovine 
tissues (e.g. liver, kidney, lung and brain). Their results showed that the 
sulphate conjugate occurs to a greater extent than the glucuronide conjugate. 
Interestingly, no glucuronide conjugation was found in the heart tissue.
Other authors maintain that glucuronides are present in the higher 
percentage (and hence only use glucuronidase for hydrolysis purposes) [13, 
14]. The best compromise is to use a combination of both types of enzyme 
(e.g. as contained in sue d’ helix pomatia). An EIA procedure for /3-agonists 
has been described by Degand et al. [15] which by-passes both sample clean­
up and enzyme hydrolysis steps; the urine samples were simply diluted to 
reduce the effects of interferences, and the antibody in the kit, directed against 
the aliphatic part of the molecule, did not distinguish between free and 
conjugated forms of salbutamol. A method by Howells et al. for salbutamol 
in liver did not use a hydrolysis procedure, and hence the results of analysis 
of incurred samples (by EIA) were probably underestimated by approximately 
40-50% [16]. Acid hydrolysis procedures have also been reported; Selinger 
et al. found that the incubation time required for enzymatic hydrolysis of 
conjugated metaproterenol was lengthy (>  180 h) and did not lead to 
complete deconjugation. The alternative acid hydrolysis procedure solved both 
these problems; plasma supernatants were incubated with 0.2 ml 2 M 
hydrochloric acid at 65 °C for 90 min to deconjugate the O-sulphate ester of 
metaproterenol [17]. A similar procedure was adopted for the hydrolysis of 
isoproterenol sulphate [18].
This study describes the development of a multi-/3-agonist 
extraction procedure using MSPD. Extracts from the procedure were 
incubated at optimum hydrolysis conditions and the determination of the 
individual /3-agonists was carried out by immunoassay.
4.2 EXPERIMENTAL
4.2.1 Reagents and Equipment
Hexane and ethanol (’Extra Pure’ grade) from Merck (Darmstadt, 
Germany), dichloromethane and methanol (both ’Hypersolv’ grade) and diethyl 
ether from BDH (Poole, UK) and double-distilled water were used. Other 
chemicals used were Analar grade from BDH, or equivalent. Sue d’helix 
pomatia (containing 100,000 units /3-glucuronidase and 1,000,000 units of 
sulphatase per ml) was supplied by Sepracor (Villeneuve la Garenne, France). 
Clenbuterol hydrochloride, salbutamol and terbutaline were obtained from 
Sigma (St. Louis, MO, USA). Cimaterol and mabuterol were supplied by 
Laboratoire d’Hormonologie (Marloie, Belgium). Bond-Elut SPE C18 
cartridges (1 ml) were supplied by Analytichem International (Harbor City, 
CA, USA).
Immunoassay kits used for determination of /3-agonists were the 
following: (a) radioimmunoassay kit, supplied by Laboratoire
d’Hormonologie (Marloie, Belgium), with antiserum which had been raised 
against salbutamol and had principal cross-reactivities relative to salbutamol 
(100%) of 118% to clenbuterol, 78% to mabuterol, 29% to terbutaline and
11.6% to cimaterol and (b) enzyme immunoassay kit supplied by R-Biopharm 
(Germany), with antiserum which had been raised against clenbuterol and had
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principal cross-reactivities relative to clenbuterol (100%) of 71 % to mabuterol, 
11% to salbutamol, 10% to terbutaline and 6% to cimaterol.
For the radioimmunoassay, 0.01 M phosphate buffer (pH 7.0), 
containing 1 g/1 gelatin and 0.1 g/1 thiomersal, was used. Dextran-coated 
charcoal was prepared by adding 2 g activated charcoal (Sigma) and 0.25 g 
dextran T70 (Pharmacia, Uppsala, Sweden) to 500 ml double-distilled water. 
The scintillation cocktail was Cocktail T (BDH). Preparative grade Sepralyte 
C18 (40 /xm, irregular size) and Isolute C18 (50 /xm) packing materials were 
supplied by Jones Chromatography (Mid-Glamorgan, UK). Preparative grade 
Bondesil C18 (40 ¡xm) material was supplied by Analytichem (Harbor City, 
CA). The C,8 material was prepared by placing it in a plastic syringe barrel 
(10 ml) and washing sequentially with two column volumes each of hexane, 
dichloromethane and methanol and drying by vacuum aspiration. Extraction 
columns were prewashed plastic syringe barrels (10 ml) and qualitative filter 
paper discs (No. 1, Whatman, Maidstone, UK) were used as frits.
4.2.2 Apparatus
A LKB Wallac 1219 Rackbeta Liquid Scintillation counter was used to 
count the radioactivity present in extracts from the MSPD procedure. 
Absorbance measurements on samples determined by EIA were carried out 
using a Dynatech Minireader with a 410 nm filter.
4.2.3 Methods
4.2.3.1 Samples
All samples of bovine liver were stored frozen until analysis. Liver 
samples from animals certified as not treated with /3-agonists were used in 
fortification studies. Liver samples from salbutamol-treated animals were 
provided by the Central Veterinary Laboratory, Weybridge, UK and were 
used for studies on determination of conjugated residues.
4.2.3.2 Fortification
The method was validated by analysis of samples fortified with 
salbutamol; levels of 0, 0.5, 1.0 and 2.5 ng of salbutamol, in 10 /xl ethanol, 
were added to 0.5 g tissue. Fortification was carried out by pipetting the 
material on to the tissue and leaving for 10 minutes prior to extraction.
4.2.3.3 MSPD Extraction
0.5 g liver was weighed into a glass mortar and 2 g of C18 packing 
material was added to the mortar and blended with the tissue, using a glass 
pestle, for 40 seconds. The mixture was removed from the mortar and
transferred to a 10 ml syringe barrel containing two filter paper discs and with 
a 100 /xl pipette tip attached to its outlet. The syringe barrel was tapped to 
settle the mixture and two filter paper discs were placed at the head of the 
column. The mixture was compressed to a volume of 4.5 ml with a syringe 
plunger (from which the rubber seal and pointed plastic retainer had been 
removed). Two types of elution procedures were adopted; either: (a) water 
wash clean-up prior to methanol elution; or (b) no water wash, but further 
clean-up by C18 solid-phase extraction.
For (a), the column was washed with 8 ml hexane and 4 ml double­
distilled water. After each wash solvent had flowed through the column, 
positive pressure was applied with a pipette bulb to remove surplus solvent. 
9 ml of methanol was added to the column, the first 1 ml of eluate (mainly 
water) was discarded and the remaining eluate collected. For (b), the column 
was washed with 8 ml hexane: diethyl ether (6: 4), after which the analytes 
of interest were eluted with 12 ml of methanol and this extract was vortexed 
and centrifuged (2000 rpm, 10 min) to remove precipitated proteins.
The methanolic extracts produced from (a) and (b) were both 
evaporated to dryness under a stream of nitrogen at 60°C on a sample 
concentrator and subjected to enzyme hydrolysis
4 .2 .3 .4  Enzyme Hydrolysis
Dried extracts from the MSPD procedure were redissolved in 0.4 ml 
phosphate-gelatin buffer (pH 5.0), 0.1 ml of sue d’helix pomatia solution 
(diluted to an appropriate concentration with buffer) was added, and the 
solution vortexed for 60 seconds. A study was carried out to determine the 
optimum and most practical hydrolysis conditions for salbutamol residues in 
incurred samples. Extracts produced from the MSPD column were incubated 
at 37°C for periods of 2 or 16 h and with enzyme concentrations of 500 U 
glucuronidase/5000 U sulphatase or 2500 U glucuronidase/25,000 U 
sulphatase. The tubes were cooled to room temperature prior to SPE clean-up 
(MSPD procedure (a)) or direct analysis (MSPD procedure (b)).
4 .2 .3 .5  Cje SPE procedure
C18 cartridges were solvated with 2 ml methanol and conditioned with 
2 ml water. The enzyme-treated MSPD extract, to which was added 0.5 ml 
water and 0.08 ml sodium hydroxide (1 M), was added to the column and 
allowed to flow under gravity. The column was washed twice with 1 ml water 
and dried thoroughly under vacuum. The column was eluted with 2 ml 
methanol, the extract evaporated under nitrogen at 60°C and redissolved in 
0.5 ml phosphate-gelatin buffer, pH 7.0.
4 .2 .3 .6  Enzyme immunoassay
The clenbuterol standard supplied with the EIA kit (and used over the 
range of 0-162 pg/well) was replaced by salbutamol, used at 0-1000 pg/well 
to allow for the relatively low cross-reactivity for salbutamol. The following 
solutions were added to the wells; 0.1 ml of enzyme conjugate, 0.02 ml of 
standard salbutamol or prepared sample and 0.1 ml of antiserum. The 
microtiter plate was shaken and incubated overnight at 5°C. After emptying 
and washing the wells, 0.05 ml aliquots of substrate and chromogen were 
added and the microtiter plate incubated at room temperature for 30 min. 
Finally, 0.1 ml of stop solution (1.0 M sulphuric acid) was added and the 
absorbance measured.
4.2.3. 7 Radioimmunoassay
0.1 ml aliquots of ethanolic standards (standard curve 0-1000 pg 
salbutamol/tube) were added to culture tubes, evaporated to dryness under a 
stream of nitrogen and redissolved in 0.5 ml phosphate gelatin buffer (pH 
7.0). 0.1 ml of sample extracts were added to 0.4 ml of phosphate gelatin 
buffer. After vortexing and incubating for 15 minutes at 37°C, 0.1 ml [3H]- 
clenbuterol and 0.1 ml antiserum were added. The tubes were incubated at 
37°C for 15 minutes and overnight at 4°C. 0.5 ml of dextran-coated charcoal
suspension was added and the tubes centrifuged at 2000 rpm for 10 minutes. 
The supernatant was decanted into scintillation vials, 10 ml of scintillation 
cocktail added and the radioactivity counted for 5 minutes.
4.3 RESULTS AND DISCUSSION
4.3.1 Direct MSPD using a water wash clean-up step
4.3.1.1 Method Optimisation
The MSPD procedure used for clenbuterol analysis (see Chapter 3) 
required a water wash (8 ml) to remove polar interferences. However, 
because of the hydrophilic nature of salbutamol, losses could be expected with 
8 ml water; hence lower volumes were evaluated. The minimal volume of 
water that could remove the red-coloured polar components from the MSPD 
column was 4 ml, and this was used in all further work.
Three different C18 materials were evaluated for this modified MSPD 
method, namely Bondesil, Isolute and Bondesil-Sepralyte C18 materials. Table
4.1 shows the comparison between the three C18 types at salbutamol 
fortification levels of 2 and 5 ng/g. Isolute material gave rise to relatively 
poor recovery of salbutamol (47-55%) followed by Bondesil (60%), but
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Table 4.1
Salbutamol
added
Salbutamol determined (ng/g)
(a) (b) (c)
(ng/g)
Mean ± SD Mean ± SD Mean ± SD
2 1.20 ± 0.05 1.20 ± 0.15 1.59 ± 0.08
5 2.31 ± 0.60 2.70 ± 0.19 4.32 ± 0.42
Direct MSPD of 2 and 5 ng/g salbutamol in liver with (a) Isolute, 
(n =  3) (b) Bondesil (n =  5) and (c) Sepralyte (n =  4) C18 
materials.
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extraction with Sepralyte material resulted in superior recoveries 
(approximately 80%). This suggests that the drug attachment on the tissue Clg 
mixture is stronger for the Sepralyte material than for the other materials, and 
the water (4 ml) does not elute the compound from the column. For the other 
materials there was partial elution of salbutamol in the water wash. For this 
reason Sepralyte C18 material was chosen for all further work involving a 
water wash step.
4.3.1.2 Enzyme Hydrolysis
Table 4.2 shows the salbutamol levels determined in incurred liver 
samples extracted by the MSPD procedure and subjected to enzyme hydrolysis 
under various conditions. Results for analysis by RIA showed a significant 
increase in the level of drug determined after enzyme hydrolysis for 2 h with 
low enzyme concentration (500/5000 U), but there was little further increase 
in residue level with extended incubation and/or higher enzyme concentration 
(2500/25000 U). In contrast, the salbutamol levels determined by EIA 
decreased with enzyme hydrolysis, and the extent of the decrease was related 
to the length of the incubation period and the enzyme concentration. The 
difference in results may be explained by differences in the antisera: the 
antiserum in the RIA kit, raised against salbutamol-hemisuccinate-BSA, and 
the antiserum in the EIA kit, raised against clenbuterol-diazo-BSA, have lower
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Enzyme hydrolysis Salbutamol (ng/g)
Glucuronidase/ Incubation period
MSPD/RIA MSPD/E1A
sulphatase
(U)
(h) Mean ±SD Mean ± SD
0 0 7.5 ± 0.6 26.5 ± 6.2
500/ 2 13.5 + 1.1 19.1 ± 6.7
5000 16 15.0 ± 1.7 16.0 ±6.3
2500/ 2 15.9 ± 3.7 15.9 ± 5.5
25000 16 14.7 ± 2.2 12.6 ± 2.7
Table 4.2 Salbutamol levels determined in liver samples from treated animals
after hydrolysis with glucuronidase/sulphatase at 37°C (n = 6)
and higher cross-reactivity, respectively, to conjugated forms of salbutamol 
compared with free salbutamol. RIA provided better reproducibility (reflected 
in the lower coefficients of variation obtained) and the higher cross-reactivities 
of this antiserum to other /3-agonists make it more suitable for multi-residue 
determination. RIA, therefore, was the technique selected for further 
validation of the MSPD procedure. The final hydrolysis conditions selected 
were 1000 U glucuronidase/10,000 U sulphatase per 0.5 ml final extract and 
incubation for 2 h at 37°C. A more concentrated enzyme activity gave rise to 
a slightly higher free salbutamol concentration, but there was a colouration of 
the extract which caused a higher background signal in the immunoassay.
4.3.1.3 Method Validation
The inter- and intra-assay variations of the method are shown in Tables
4.3 and 4.4. Good recovery of residue was determined at the 1 ng/g (97%), 
level but lower recoveries were determined for the 2 ng/g (87%) and the 5 
ng/g (65%) levels. These apparent low recoveries are due to inaccuracy of 
the radioimmunoassay procedure rather than to losses in the extraction 
procedure; a relatively high non-specific binding (NSB) value occurs in 
extracts prepared by the MSPD procedure and its negative influence on 
quantitation increases with concentration of analyte in the extract. A similar 
effect was observed for the assay of clenbuterol by MSPD (see Chapter 3),
Salbutamol
added
(ng/g)
Salbutamol determined (ng/g) 
Mean ± SD CV (%)
Table 4.3
1 0.97 ± 0.09 3.8
2 1.73 ±  0.25 14.4
5 3.27 ±  0.62 18.9
Inter-assay variation for MSPD/RIA determination of salbutamol 
in liver (n = 5); Extracts measured against a salbutamol standard 
curve without control tissue extract.
Salbutamol
added
(ng/g)
Salbutamol determined (ng/g) 
Mean ± SD CV (%)
1 0.89 ±  0.12 14.0
5 3.50 ±  0.60 17.0
Table 4.4 Intra-assay for MSPD/RIA determination o f salbutamol in liver
(n = 6).
and could be overcome by use of a standard curve containing tissue extract for 
the radioimmunoassay. The intra-assay results showed acceptable variation 
within a single assay for samples fortified at 1 and 5 ng/g (Table 4.4).
4.3.1.4 Limit o f detection
A tentative limit of detection for the MSPD/RIA procedure was 
determined by analysis of liver samples free of salbutamol residues. The 
mean value for these samples (n =  8) was 0.35 ng/g (_+ 0.11 ng/g, n =  8). 
The limit of detection, calculated as the mean +  3 times the standard 
deviation, was found to be 0.69 ng/g.
4.3.1.5 Incurred sample analyses
Liver samples from animals treated with salbutamol were analysed 
using the developed procedure. Table 4.5 shows the salbutamol levels 
determined in incurred samples before and after enzyme hydrolysis. The 
results show that at the three dose levels used with a withdrawal period 
selected to give residue-positive samples, 40-45% of the residue occurs in the 
liver in a conjugated form. These results are consistent with a salbutamol 
deconjugation study carried out by Montrade et al. [12]; using an extraction 
procedure involving "mixed phase" SPE sample clean-up on a liver
Sample Treatment Salbutamol determined
fne/sf)
No. Dose (IM, 
Hg/kg)
Wididrawal
period
CO
(a)
Mean ± SD
(b)
Mean ± SD
1 I 0.2 18 0.88 ± 0.05 1.54 ±0.18
2 1.0 18 7.95 ±  0.89 13.68 ± 1.57
3 5.0 18 26.38 ± 6.50 44.40 ± 8.74
4 II 2.01 168 0.23 ± 0.08 0.26 ± 0.17
5 2.01 168 0.16 ± 0.08 0.29 ± 0.13
1 Dose given twice daily for 4 days
4.5 Salbutamol levels determined in liver samples from treated animals
by MSPD/RIA before (a) and after (b) hydrolysis using 
glucuronidase/ sulphatase (n = 4).
homogenate and GC-MS analysis, these authors found that 42-50% of the 
salbutamol residues occur as conjugates. Table 4.5 also shows the results for 
analysis of liver samples of animals which had longer withdrawal periods of 
7 days. No residues were detectable above the limit of determination of the 
method. This was to be expected as salbutamol, possessing a catechol 
structure, is metabolized by the COMT pathway (catechol O-methylation 
transferase reaction), resulting in a short half-life [8].
4.3 .1 .6  Multiresidue analysis
The developed method was applied to the analysis of other /3-agonists. 
The method was tested for clenbuterol, mabuterol, terbutaline and cimaterol 
using liver samples fortified with these drugs at 2 ng/g. Samples were 
fortified, also, with terbutaline and cimaterol at 10 ng/g because of their 
relatively low cross-reactivities to the RIA antiserum. Table 4.6 shows results 
for analysis of these fortified samples. Residue levels were determined, also, 
using clenbuterol and mabuterol standard curves. Salbutamol (or mabuterol) 
standard curves are most suitable for a multi-residue procedure with 
clenbuterol, salbutamol and mabuterol detectable at 1 ng/g or less and 
terbutaline detectable at about 2 ng/g. Cimaterol, because of its low cross­
reactivity to the antiserum, gave a result below the limit of detection of the 
method for fortification level of 2 ng/g. Cimaterol would be detectable at a
(3-agonist Amount  Amount determined fag/g)_______
added added Clenbuterol Salbutamol Mabuterol
(ng/g) standard curve standard curve standard curve
Mean + SD Mean ± SD Mean ± SD
Clenbuterol 2 1.36 ±0.21 2.37 ± 0.28 2.30 ± 0.10
Salbutamol 2 0.80 ±0.11 1.33 ± 0.05 1.46 ± 0.10
Mabuterol 2 0.98 ± 0.23 1.66 ± 0.28 1.73 ± 0.14
Terbutaline 2 0.38 ± 0.07 0.60 ± 0.01 0.76 ± 0.04
Cimaterol 2 0.24 ± 0.02 0.38 ± 0.08 0.51 ± 0.09
Terbutaline 10 1.32 ± 0.05 2.25 ±0.11 2.25 ± 0.34
Cimaterol 10 1.03 ±0.04 1.73 ± 0.20 1.83 ± 0.34
Table 4.6 Determination o f various (3-agonists, by MSPD/RIA using 
clenbuterol, salbutamol and mabuterol standard curves prepared 
without control tissue extract..
level of about 4 ng/g. Taking into consideration the differing cross-reactivities 
of the ¡3-agonists to the assay antiserum, the MSPD extraction procedure gives 
reasonable recovery for all 5 substances tested and is appropriate as a 
multiresidue extraction method.
4.3.2 Linkage of MSPD with a C18 SPE clean-up step
4.3.2.1 Method validation
An inter-assay variation of salbutamol, clenbuterol and mabuterol, at 
1 ng/g and 2 ng/g levels, measured using salbutamol standard curves with and 
without tissue extract was carried out. Table 4.7 shows the results of the the 
former option. The table also provides comparisons between the two main Clg 
material brands (Bondesil and Isolute). The use of an extract containing 
standard curve gives the best recovery data, as was found for the clenbuterol 
assay in Chapter 3. For either C]8 material type, the measured recovery for 
salbutamol is 79% or greater, for clenbuterol greater than 100% and for 
mabuterol 64% or greater; these results indicate high recovery of the (3- 
agonists by the MSPD/SPE procedure with the relatively high and low 
recoveries obtained for clenbuterol and mabuterol, respectively, being 
explained by the cross-reactivity of the antiserum towards these compounds 
(for clenbuterol it is 118% and for mabuterol it is 78%).
The two grades of C18 material gave comparable results, for example
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p-agonist determined (ng/g)
Table 4.7
{3 -agonist
added
(ng/g)
n (a) Bondesil C,g (b) Isoiute C18
Mean ± SD CV(%) Mean ± SD CV{%)
1 (S) 5 0.79 ± 0.11 13.9 0.85 ± 0.22 26.1
2 5 1.80 ± 0.27 15.0 1.79 ± 0.21 11.7
I (C) 5 1.15 ± 0.22 19.1 1.10 ± 0.21 19.1
2 5 3.19 ± 0.82 25.7 2.42 ± 0.51 21.1
1 (M) 5 0.69 ± 0.06 8.7 0.69 ±0.11 15.9
2 5 1.32 ± 0.19 14.4 1.27 ± 0.17 13.4
Inter-assay variation o f salbutamol' (S), clenbuterol (C) and 
mabuterol(M) at 1 and 2 ng/g levels in liver extracts from 
MSPD/SPE/RIA. The performance of the two Clg brands was 
evaluated and the 0 -agonists were determined against a salbutamol 
standard graph containing tissue extract.
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0.79 ng/g (Bondesil) and 0.85 ng/g (Isolute) for salbutamol at 1 ng/g 
recovery. There was a difference, however, between C18 materials for the 
clenbuterol 2 ng/g level due mainly to a highly inflated result being obtained 
for one sample (4.58 ng/g, Bondesil material). These results show that the 
method works well for different brands of Clg material.
The inter-assay data using standard curve without tissue extract (results 
not shown) demonstrates that lower recovery values were being obtained. 
However, taking into account the cross-reactivity of the antiserum, the mean 
measured recovery for all three compounds was >  65%. Hence, a curve 
without tissue extract may be used for routine work. The intra-assay variation 
data for liver samples fortified with /3-agonists at the 2 ng/g level is provided 
in Tables 4.8 (salbutamol standard curve with added tissue extract). The 
coefficients of variation were always less than 20%. This is considered 
acceptable in view of the nature of the sample matrix. For the Isolute 
material, the recovery of mabuterol was low (mean recovery, corrected for 
cross-reactivity, of 52%) compared to that obtained consistently in the inter­
assay study. For the other compounds the recovery was always greater 80%, 
irrespective of the C18 material used.
Table 4.8
p-agonist
added
(ng/g)
n
P-agonist determined (ng/g)
(a) Bondesil Cl8 (b) Isolute Cu
Mean ± SD CV(%) Mean ± SD CV(%)
2 (S) 4 2.24 ± 0.17 7.8 1.87 ±0.21 11.2
2 (C) 4 2.54 ± 0.48 18.9 1.99 ±0.17 8.5
2 (M) 4 1.51 ±0.26 17.2 0.82 ±0.12 14.6
Intra-assay variation of 2 ng/g salbutamol (S), clenbutero! (C) and 
mabuterol (M) in liver extracts from MSPD/SPE/RIA using either 
Bondesil or Isolute C18 material. The extracts were determined 
against a salbutamol standard curve containing tissue extract.
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4 .3 .2 .2  Limit o f  detection
Limits of detection for the MSPD/RIA method were determined by 
analysis of liver samples (n =  7), free of ß-agonist residues. The limits, 
calculated as the mean +  3 times the standard deviation, were determined 
depending on the brand of C18 material used and on the type of curve (without 
or with tissue extract) used:
(a) Bondesil/with tissue extract curve:
0.17 ng/g (mean response +  SD = 0.0260 ng/g +  0.048 ng/g)
(b) Bondesil/without tissue extract curve:
0.16 ng/g (mean response +  SD =  0.029 ng/g +  0.045 ng/g)
(c) Isolute/with tissue extract curve:
0.57 ng/g (mean response +  SD = 0.071 ng/g +  0.165 ng/g)
(d) Isolute/with out tissue extract curve:
0.28 ng/g (mean response +  SD =  0.037 ng/g +  0.082 ng/g)
Apart from the results for the Isolute material determined by a curve 
without tissue extract (c), the limits fall well below the maximum residue limit 
(MRL) of 0.5 ng/g [10]. For (c) there was one negative control value giving 
a high background level (0.4 ng/g), resulting in a high standard deviation and 
consequently a high limit of detection.
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4.4.2.3 Incurred sample analyses
Liver samples from animals treated with salbutamol and clenbuterol 
were analysed using the developed procedure. Again, the method was 
evaluated with respect to Clg material brand and curve type. Table 4.9 shows 
the results of these analyses. As for the inter-assay analysis, there was no 
significant difference between the results obtained using Bondesil or Isolute Clg 
materials. For the incurred salbutamol sample (at approx. 1.2 ng/g) a lower 
result was obtained with this method than was obtained by direct MSPD 
extraction (1.54 ng/g). The values obtained for the clenbuterol incurred 
sample (i.e. 4.34 and 3.96 ng/g) were somewhat inflated over that obtained 
before (3.60 ng/g) using a clenbuterol standard curve containing tissue extract; 
the inflated results are probably due to the higher cross-reactivity to 
clenbuterol (118%) in this assay.
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Residue determined (ng/g)
Sample
A
B
MSPD/SPE/RIA method (n = 5)
Previous Bondesil C,8 Isolute CIS
methods ______________________________
Mean ± SD Mean ± SD
1.541 1.14 ±0.31 1.17 ±0.19
3.602 4.34 ± 1.55 3.96 ± 1.43
Results for residue-positive samples containing salbutamol 
(sample A) and clenbuterol (sample B) determined by the 
developed procedure. Results are compared to previous methods, 
either direct MSFD/RIA (') or solvent extraction/RIA (2).
4.5 CONCLUSIONS
The ease of extraction of clenbuterol by MSPD (Chapter 3) indicated 
that the technique might be suitable, also, for other /3-agonist compounds; 
compounds similar in structure to clenbuterol like mabuterol and cimaterol 
were obvious candidates. The phenolic /3-agonists, being more polar and 
ionizable were, however, liable to be removed in the water wash. The present 
study demonstrates that good recovery of salbutamol may be obtained, 
depending on the Clg material used. Of the three C18 materials tested 
Sepralyte retains salbutamol most strongly and allows the use of a water wash. 
However, to provide a more universal procedure, i.e. a procedure which could 
extract a range of /3-agonists irrespective of the material brand, the water wash 
step was eliminated and replaced by solid-phase extraction. Using this 
purifying step, recoveries of 80% or better were achieved for all three 
compounds tested. Moreover, the procedure has the capability to detect 
residues below the 1 ppb level.
The inclusion of a hydrolysis step was necessary for residues which 
occur as conjugates. Results from other studies show that, for salbutamol, 
two main conjugates are present in liver samples, namely glucuronides and 
sulphate esters [12]. The incorporation of a post-MSPD enzyme hydrolysis 
step into the procedure deconjugates the residues to give an accurate value for 
total /3-agonists present. A short hydrolysis time (2 h) coupled with a low
enzyme concentration was found to be sufficient to achieve deconjugation. 
The results show that 40-45 % of salbutamol residues occur in the liver in a 
conjugated form.
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CHAPTER 5
SUPERCRITICAL FLUID EXTRACTION AND 
CHROMATOGRAPHY OF /3-AGONISTS
5.1 INTRODUCTION
A supercritical fluid (SF) may be described as a dense gas which 
possesses physico-chemical properties intermediate between those of liquids 
and gases. This state is reached by bringing the substance above its critical 
temperature (Tc) and pressure (Pc). A SF may be defined from the pressure- 
temperature phase diagram shown Figure 5.1 (supercritical fluid, carbon 
dioxide). The solvent strengths of SFs approach those of liquid solvents as 
their density is increased, thereby having the capacity to dissolve a variety of 
solutes, even those of high molecular weight and low volatility. In addition, 
because SFs have solute diffusivities an order of magnitude higher, and 
viscosities an order of magnitude lower, than liquid solvents they have much 
better mass transfer characteristics. Table 5.1 shows a comparison in 
properties between a gas, a SF and a liquid. The SF possesses the most ideal 
properties for use as a mobile phase in chromatograpic science; its low 
viscosity characteristic allows a lower pressure drop over a column than for 
a liquid for a given flow rate. This low column pressure drop results in the 
column having apparently more theoretical plates per meter and increased 
chromatographic efficiency. Its higher analyte diffusivity causes narrower 
chromatographic peaks and hence better sensitivity [1].
The solvent strength of a SF can be easily controlled, unlike a liquid 
where the solvent strength is essentially constant irrespective of the
F ig u re  5.1 Pressure-temperature phase diagram for supercritical carbon 
dioxide.
Mobile Density Viscosity Diffusivity
phase (g m l1}) (g cm 1 s'1) (cm2 s 1)
Gas 10'3 0.5-3.5 X  10'4 0 .01- 1.0
SF 0.2-0.9 0.2-1.0 X  10° 3.3-0.1 X  IO’4
Liquid 0.8-1.0 0.3-2.4 X  IO'2 0.5-2.0 X  10'5
T ab le  5.1 Comparison in physical properties, from a chromatographic point
of view, for gas, liquid and supercritical fluid (SF) mobile phases.
Compound Boiling 
point (°C)
Tcr (°C) Per (bar) Density
(g/ml)
Carbon dioxide -78.5 31.3 72.9 0.45
Nitrous oxide -89.0 36.5 71.4 0.46
Ammonia -33.4 132.3 111.3 0.24
Xenon -107.3 16.6 58.4 1.10
T ab le  5.2 The physical properties, relevant to SFE and SFC, of various SF 
substances.
extraction conditions. The solvent strength of the SF depends upon the 
temperature and pressure applied to it. At a constant temperature the 
application of a low pressure produces a low density, and hence relatively 
non-polar, SF and which will result in the extraction of non-polar analytes. 
Increasing the pressure to different points allows the selective fractionation of 
analytes according to their solubility in the SF. Figure 5.2 shows how 
supercritical carbon dioxide is affected by various temperature/pressure 
conditions.
A wide variety of substances may be used as SFs but, practically, only 
three or four have been found suitable. Table 5.2 shows the characteristic 
physical properties of these substances. Carbon dioxide is by far the most 
used. It is inert, inexpensive and non-toxic and has low Tc and P0 values. 
Nitrous oxide possesses similar Tc and Pc values but there have been some 
serious accidents in its usage [2, 3] due to its oxidising properties. Xenon, 
with Tc and Pc values of 16.6°C and 58.4 bar has almost ideal properties but 
it is too expensive for routine use in analysis. Supercritical ammonia is 
applicable to polar analytes but has higher Tc and Pc values and is toxic and 
corrosive. Other substances have also been used (for example 
chlorodifluorocarbon [4]) but the vast majority of applications report the use 
of supercritical carbon dioxide (SC-C02).
The two major analytical applications which utilise SFs are supercritical 
fluid extraction (SFE) and supercritical fluid chromatography (SFC). The
Temperature (°C)
Figure 5.2 Plot o f carbon dioxide density vs temperature at various pressures.
former technique may be viewed as an analyte isolation procedure analogous 
to liquid-liquid extraction whereas the latter is a chromatographic technique 
with the combined separation properties of both HPLC and GC. A 
combination of both techniques (i.e. SFE/SFC) is a possible sample clean-up 
option [5]. Extracts from SFE may be analysed by SFC but in most cases 
HPLC or GC is preferred [6-8]. A SFE apparatus consists of a pump which 
directs the SF through a heated sample vessel where the analytes are extracted 
and then swept to a collection device via a flow restrictor from which the 
depressurised SF is vented. The analytes may be rinsed from the collection 
device with an organic solvent (normally methanol). SFE can be performed 
in dynamic mode (continuous flow of SC-C02 through the extraction cell) or 
static mode (fixed amount of SC-C02 in the extraction cell) or even a 
combination of both. A schematic diagram of the SFE apparatus is shown in 
Figure 5.3.
SC-C02 is relatively non-polar hence its extracting capacity for medium 
to high polar analytes depends on the application of high temperature/pressure 
conditions [9] or the introduction of a modifier solvent in a low percentage 
[10, 11]. Many reviews have appeared which focus on the merits of SFE and 
ways of optimising extraction conditions for various analytes [12 , 13]. The 
bulk of the literature reporting SFE deals with SF-C02 extractions of relatively 
non-polar components like pesticides [14-16], environmental contaminants 
(e.g. PCBs, PCHs) [17-22] and fats/oils [23-26]. For more polar compounds
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Figure 5.3 Schematic of the HP-7680T supercritical fluid extractor.
the addition of a modifying solvent was required; for instance Eureby et al. 
found that extracting tipredane (a corticosteroid) with pure supercritical C 02 
gave low recovery whereas addition of a modifier (ethanol, up to 33% v/v) 
gave rise to recoveries of greater than 80% [6]. Similar experiences were 
reported by other authors [10 , 11]. Although extracts from SFE need not be 
confined to SFC analysis, an "in-line" SFE-SFC linkage is advantageous as the 
injection solvent is the same as the mobile phase, i.e. the output characteristics 
from the first instrument and the input characteristics of the second instrument 
are compatible.
SFC provides an alternative to HPLC and GC techniques for the 
separation and detection of analytes from sample extracts. The advantages of 
using SFs for separation purposes have already been discussed. Additionally, 
SFC is compatible with a wide range of detectors in use with both HPLC and 
GC. The ultraviolet detection option is extremely popular and applicable to 
most analytes possessing a chromophore [7], The combination of SFC with 
a mass spectrometer gives additional sensitivity and provides information on 
compound structure [5, 27]. Suitable stationary phases are not unlike those 
used in other chromatographic techniques; packed columns (as in HPLC) 
containing a range of functional groups (C18, C8, NH2, etc) bonded to silica 
and open-tubular columns with stationary phases similar to those used in 
capillary GC except that the inside diameter is smaller and the stationary phase 
must be immobilised. A schematic diagram of a SFC apparatus is provided
in Figure 5.4. The relative non-polar nature of supercritical C 02 means that 
the bulk of extractions/separations have been of relatively non-polar analytes. 
For SFE/SFC to become a standard sample extraction/analysis techniques, 
however, their application to polar analytes must be addressed. Most 
drugs/drug metabolites contain one or more polar functional groups and the 
extraction methodologies used are usually lengthy requiring for example 
liquid-liquid or solid phase extraction. With certain modifications these 
extractions may be performed more efficiently by SFE. Many authors have 
reported methods applicable to the more polar drug compounds; for instance 
Cross et al. extracted sulphonamides from liver after first dispersing the 
sample on diatomaceous earth. The extraction was short (5 min) and recovery 
of the various drug compounds was in the order 53-93% [28]. Khundker et 
al. also extracted a drug compound, ibuprofen, using unmodified SC-C02 
although high temperature (70°C) and high density (0.7 g/ml) conditions were 
required [9]. A home-made SFE apparatus was described and built by 
Maxwell and co-workers which could apply twice the maximum pressure of 
its commercial counterpart. Methods were reported for the extraction of ten 
nitrosamines from meat samples [29] and three nitrobenzamide antimicrobial 
drugs from liver samples [30]. For more efficient extraction of polar drugs, 
an organic modifier must be added to the supercritical fluid. Liu and co­
workers found that 5 % methanol in SC-C02 was sufficiently polar to extract 
flavone [10] and mebeverine [11] from blood plasma. Higher methanol
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Figure 5.4 Schematic of a packed column SFC system.
concentraions (between 17 and 33%) were necessary to extract tipredane 
efficiently [6]. A novel on-line SFE-SFC-MS-MS technique was described by 
Ramsey et al.; the mainly non-polar components of kidney tissue were 
washed from the extraction vessel with SC-C02, after which the test analytes 
(hexesterol, diethylstilbesterol) were eluted and separated via gradient elution 
using SFC to the mass spectrometer for detection [5]. Alternative extraction 
methodologies for pharmaceuticals/polar analytes include the use of 
supercritical fluid-nitrous oxide extraction [31] and in-situ chemical 
derivatisation [32].
This chapter examines appropriate conditions for the extraction (using 
SFE) and separation (using SFC) of /3-agonists. The /3-agonists were first 
extracted from an inert matrix (filter paper) after optimisation of various 
parameters. The optimised procedure was applied to the extraction of 
mabuterol from liver dispersed on both Celite and C18 material. The use of 
a C18/tissue blend was a novel approach to linkage of MSPD with SFE. The 
extracted samples were assayed by SFC.
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5.2 EXPERIMENTAL
5.2.1 Reagents and materials
HPLC-grade methanol was obtained from Rathburn (Walkerburn, UK). 
Glass wool and triethylamine were obtained from Sigma (Poole, Dorset, UK). 
Instrument-grade liquid carbon dioxide, supplied in a cylinder with a syphon 
tube, was obtained from BOC (London, UK). Clenbuterol hydrochloride, 
salbutamol and terbutaline were purchased from Sigma (St. Louis, MO, USA). 
Mabuterol and cimaterol were supplied by BGA (Berlin, Germany). Solid 
support materials were reagent grade Celite (Supelco, Pennsylvania, USA) and 
octadecylsilane material ("Isolute" Clg end-capped, 40 ¿im), (International 
Sorbent Technology (1ST), Mid Glamorgan, UK). Qualitative filter paper 
(No. 1) was supplied by Whatman (Maidstone, Kent, UK).
5.2.2 Apparatus
For supercritical fluid chromatography a Hewlett Packard (HP)-SFC 
system with UV detection coupled to a HP Series 1050 modifier pump was 
used. A 3 fim packing, amino-bonded column, 25 cm x 4.6 mm, (Capitol 
HPLC, Edinburgh, UK) was used to separate the /3-agonists. Extractions were 
performed with a HP Model 7680T supercritical extraction system, also
coupled to a HP Series 1050 modifier pump.
5.2.3 Methods
5.2.3.1 Samples
Samples of bovine liver from animals certified as not treated with (3- 
agonists were homogenised and stored frozen until required for assay.
5.2.3.2 Supercritical fluid chromatography (SFC)
Since previous work had shown that a high % methanol content in the 
SC-C02 was required for the /5-blockers, compounds structurally-related to /5- 
agonists [33], methanol-modified SC-C02 was evaluated for the /3-agonists. 
A number of HPLC columns (25 cm x 4.6 mm) containing C18, -OH and -NH2 
functional groups bound to silica, were tested for their capacity to separate the 
compounds. Triethylamine (TEA) was added at a concentration of 1 % v/v in 
methanol to block residual silanol groups and ensure good peak shape. A 
column temperature of 55°C was maintained to ensure supercritical conditions.
-176-
The conditions used for SFC were as follows:
Oven temperature: 55 °C
Supercritical C 02: 250 bar
Mobile phase: SC-C02/methanol/TEA(75 % /24.75 %/0.25 %)
Flow rate: 2.0 ml/min
Detection: UV at 244 nm
Column: Amino 3 ¿im packing, 25 cm x 4.6 mm,
5.2.3.3 Supercritical fluid extraction (SFE)
5.2.3.3.1 Extraction from filter paper
100 ¡x\ aliquots of 1 mg/ml solutions of the /3-agonists (in methanol) 
were added to filter paper and, after evaporation of the methanol, the filter 
paper was placed into the extraction thimble. The following parameters were 
optimised: fluid density, extraction temperature, extraction time and modifier 
(methanol) content. The extraction was performed both in dynamic and static 
modes. The extracted fluid was swept onto a metal (stainless steel) trap which 
was then rinsed with methanol and the extract was analysed by SFC.
The conditions used for SFE were as follows:
Density: 0.84 g/ml
Chamber temperature: 70°C
Flow rate: 2.0 ml/min
Modifier content: 25%
Extraction time: 30 min
5.2.3.3.2 Extraction from liver
The solid support materials, Celite and C18 were evaluated for their 
capacity to disperse the liver samples. Mabuterol was the test analyte. Liver 
(0.5 g) was weighed into a glass mortar and fortified with 50 fxg (in 50 ¡A) 
mabuterol standard. After 10 min, 2 g of C18 material or 0.9 g Celite was 
added and the liver was blended until thoroughly mixed (40-60 s). The 
mixture was added to the extraction thimble and both ends of the thimble were 
blocked by glass wool. The extraction conditions described in section
5.2.3.3.1 were then applied.
5.3 RESULTS AND DISCUSSION
A number of stationary phases were tested, but only one, an amino 
column, gave good separation of the compounds. In fact, for the bulk of 
applications to pharmaceutical substances, the choice is usually between cyano 
or amino types of modified silica [34]. When all five compounds were 
injected onto the SFC system, the three least polar compounds (in order of 
increasing polarity) mabuterol, clenbuterol and cimaterol eluted within the first 
five minutes and these aniline /3-agonists were well separated from each other 
(Figure 5.5). The phenolic /3-agonists, salbutamol and terbutaline did not elute 
within the first 20 min. It is most likely that these compounds, which are 
relatively insoluble in the supercritical fluid, are highly retained on the 
stationary phase. Because of these results, further work was concentrated 
solely on the separation and extraction of the aniline type compounds.
Extraction in the static mode using a long extraction time (30 min) 
proved to be more efficient than its dynamic mode counterpart and was thus 
chosen for all further work. Extraction of the aniline /3-agonists from filter 
paper using pure supercritical C 02 was totally ineffective due to the 
compounds’ high polarity. The polarity of the supercritical C 02 was increased 
by addition of a modifier, methanol. Optimum extraction was achieved with 
a high methanol content (25 %). A high temperature (70°C) coupled with high 
density supercritical C 02 (0.84 g/ml) were also necessary conditions to extract
Figure 5.5 Supercritical fluid chromatogram of a mixture of 1 |ig (on column)
o f mabuterol (a), clenbuterol (b) and cimaterol (c). Conditions as 
explained in text.
the compounds. Figure 5.6 shows an SFE extract from filter paper containing 
mabuterol and clenbuterol (1 fxg on column) using optimum extraction 
conditions. The extraction efficiency was 89% for mabuterol and 80% for 
clenbuterol. For evaluation of the solid supports, Celite and Clg, mabuterol 
was chosen as the test analyte. Figure 5.7 shows the chromatograms obtained 
for Celite and Qg based extracts. The negative control liver extract (Figure 
5.7 (a)) contains a main interferant at 3.3 min and other smaller interferants 
(after 5 min) but the area around the retention time for mabuterol (3.8 min) 
is free from interferences. When the mabuterol-fortified (50 ¡ig/0.5 g) extract 
was injected, however, the recovery of drug was only 9% (Figure 5.7 (b)).
For C,g material better results were achieved: for the mabuterol-fortified 
extract a recovery of 31 % was obtained (Figure 5.7 (c). Similar results were 
obtained for a repeat of these extractions (Celite-5%, Clg-27%). These 
preliminary results indicate that, with the available equipment, highly modified 
supercritical fluid is required to extract some of the /3-agonists. The level of 
drug used for this evaluation of SFE (100 ppm) was very high but such 
fortification was used so that UV detection would not be limiting. The ideal 
determination technique, in this case, would be immunoassay which could 
detect /3-agonists at less than 1 ppb. When a more comprehensive study is 
undertaken, in which SFE conditions would be optimised for more efficient 
extraction, the SFE-immunoassay linkage would be explored.
Figure 5.6 Supercritical fluid chromatogram of an extract obtained by SFE 
from filter paper fortified with 100 \iglml of 1 mg/ml 
concentrations of mabuterol (a) and clenbuterol (b).
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Figure 5.7 Supercritical fluid chromatograms of liver extracts, (a) negative
control liver (with Celite) fortified with methanol, (b) negative 
control liver (with Celite) fortified with 100 |_ig/ml mabuterol and 
(c) negative control liver (with C18) fortified with 100 |ig/ml 
mabuterol.
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5.4 CONCLUSIONS
The work carried out shows that SFC is a promising technique for the 
separation of aniline-type /3-agonists. The phenolic compounds which are 
extremely polar, interacted with the column functional groups to the extent 
that they did not elute in a reasonable analysis time. The conditions for 
extraction by SFE were extremely harsh and it is questionable whether 
supercritical conditions were really being applied. However, compounds like 
mabuterol and clenbuterol may be extracted from an inert matrix (filter paper) 
at an 80% recovery efficiency. From liver samples the recovery was much 
lower; mabuterol was extracted at between 5 and 9 % when dispersed on Celite 
and at 27 to 31 % when dispersed on C18 material. It is interesting to note that 
samples prepared by an MSPD type procedure gave higher recovery, 
especially as there are no references in the literature reporting C18 as a sample 
dispersant.
The hydrophilic /3-agonists (salbutamol, terbutaline), would appear to 
be unsuitable candidates for extraction in supercritical C 02 or even highly- 
modified supercritical C 02. Alternative procedures which might be studied 
include changing to a more polar supercritical fluid (e.g. ammonia) or in-situ 
derivatisation of the compounds to make them less polar and, therefore, more 
available to the supercritical fluid.
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